**UNITED STATES**



**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**FORM 10-Q**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended September 28, 2018**

**Commission File Number 1-16137**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_



|  |  |  |  |
| --- | --- | --- | --- |
|  | **INTEGER HOLDINGS CORPORATION** | | |
|  | **(Exact name of Registrant as specified in its charter)** | | |
|  | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | |  |
| **Delaware** | **16-1531026** | | |
| **(State of** |  |  | **(I.R.S. Employer** |
| **Incorporation)** |  |  | **Identification No.)** |
|  |  | **5830 Granite Parkway** | |
|  |  | **Suite 1150** | |
|  |  | **Plano, Texas 75024** | |
|  |  | **(Address of principal executive offices)** | |
|  | **(214) 618-5243** | |  |
|  |  | **(Registrant’s telephone number, including area code)** | |
|  |  |  |  |

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by checkmark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

☒

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares outstanding of the Company’s common stock, $0.001 par value per share, as of October 26, 2018 was: 32,382,687 shares.

**INTEGER HOLDINGS CORPORATION**

**Form 10-Q**

**For the Quarterly Period Ended September 28, 2018**

**TABLE OF CONTENTS**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | **Page** | | |
| [**PART I—FINANCIAL INFORMATION**](#page3) | | | | | | | | | | | | | | | |  |  |  |
| ITEM 1. | | [Financial Statements](#page3) | | | |  | | | | | | | | | |  | | [3](#page3) |
|  |  | [Condensed Consolidated Balance Sheets (Unaudited)](#page3) | | | | | | | | | | | | | | [3](#page3) | | |
|  |  |  |  |  |  | |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | [Condensed Consolidated Statements of Operations (Unaudited)](#page4) | | | | | | | | | | | | | | [4](#page4) | | |
|  |  |  |  |  |  | |  | |  |  |  |  |  |  |  |  |  |  |
|  |  | [Condensed Consolidated Statements of Comprehensive Income (Unaudited)](#page5) | | | | | | | | | | | |  | |  | | [5](#page5) |
|  |  | [Condensed Consolidated Statements of Cash Flows (Unaudited)](#page6) | | | | | | | | | | | | | | [6](#page6) | | |
|  |  |  |  |  |  | |  | |  | |  |  |  | |  |  |  |  |
|  |  | [Condensed Consolidated Statement of Stockholders’ Equity (Unaudited)](#page7) | | | | | | | | | | |  | | |  | | [7](#page7) |
|  |  | [Notes to Condensed Consolidated Financial Statements (Unaudited)](#page8) | | | | | | | | | | | | | | [8](#page8) | | |
|  |  |  |  |  |  | |  | |  | | |  | | |  |  |  |  |
| ITEM 2. | | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#page33) | | | | | | | | | | | | |  | [33](#page33) | | |
|  |  |  |  |  |  | |  | |  | | | | | |  |  |  | |
| ITEM 3. | | [Quantitative and Qualitative Disclosures About Market Risk](#page51) | | | | | | |  | | | | | |  | [51](#page51) | | |
|  |  |  |  |  |  | |  | |  | | | | | | |  |  | |
| ITEM 4. | | [Controls and Procedures](#page51) | | | | | | |  | | | | | | | [51](#page51) | | |
|  |  |  |  |  |  | |  | | | | | | | | |  |  |  |
| [**PART II—OTHER INFORMATION**](#page51) | | | | | | | | | | | | | | | |  |  |  |
| ITEM 1. | | [Legal Proceedings](#page52) | | | | | | | | | | | | | | [52](#page52) | | |
|  |  |  |  |  |  | | | | | | | | | | |  |  | |
| ITEM 1A. | | [Risk Factors](#page52) | |  |  | | | | | | | | | | | [52](#page52) | | |
|  |  |  |  |  | | | | | | | | | | | |  |  | |
| ITEM 6. | | [Exhibits](#page52) |  |  | | | | | | | | | | | | [52](#page52) | | |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | |
| [SIGNATURES](#page53) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | [53](#page53) | | |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

- 2 -

**PART I—FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

**INTEGER HOLDINGS CORPORATION**

**CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  | **September 28,** | |  | **December 29,** |  |
| **(in thousands except share and per share data)** |  | **2018** |  |  | **2017** |  |
| **ASSETS** |  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| Current assets: |  |  |  |  |  |  |
| Cash and cash equivalents | $ | 22,881 |  | $ | 37,341 |  |
|  |  |  |  |  |  |  |
| Accounts receivable, net of allowance for doubtful accounts of $0.6 million and |  |  |  |  |  |  |
| $0.5 million, respectively |  | 200,147 |  |  | 194,845 |  |
| Inventories |  | 193,631 |  |  | 176,738 |  |
|  |  |  |  |  |  |  |
| Prepaid expenses and other current assets |  | 12,008 |  |  | 16,239 |  |
| Current assets of discontinued operations held for sale |  | — | |  | 106,746 |  |
|  |  |  |  |  |  |  |
| Total current assets |  | 428,667 |  |  | 531,909 |  |
| Property, plant and equipment, net |  | 232,108 |  |  | 235,180 |  |
|  |  |  |  |  |  |  |
| Goodwill |  | 834,520 |  |  | 839,870 |  |
| Other intangible assets, net |  | 825,359 |  |  | 862,873 |  |
|  |  |  |  |  |  |  |
| Deferred income taxes |  | 3,618 |  |  | 3,451 |  |
| Other assets |  | 31,724 |  |  | 30,428 |  |
|  |  |  |  |  |  |  |
| Noncurrent assets of discontinued operations held for sale |  | — | |  | 344,634 |  |
| Total assets | $ | 2,355,996 |  | $ | 2,848,345 |  |
| **LIABILITIES AND STOCKHOLDERS’ EQUITY** |  |  |  |  |  |  |
| Current liabilities: |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| Current portion of long-term debt | $ | 37,500 |  | $ | 30,469 |  |
| Accounts payable |  | 69,270 |  |  | 64,551 |  |
|  |  |  |  |  |  |  |
| Income taxes payable |  | 16,298 |  |  | 5,904 |  |
| Accrued expenses |  | 54,922 |  |  | 60,376 |  |
|  |  |  |  |  |  |  |
| Current liabilities of discontinued operations held for sale |  | — | |  | 47,703 |  |
| Total current liabilities |  | 177,990 |  |  | 209,003 |  |
|  |  |  |  |  |  |  |
| Long-term debt |  | 916,694 |  |  | 1,578,696 |  |
| Deferred income taxes |  | 210,303 |  |  | 140,964 |  |
|  |  |  |  |  |  |  |
| Other long-term liabilities |  | 11,678 |  |  | 11,335 |  |
| Noncurrent liabilities of discontinued operations held for sale |  | — | |  | 14,966 |  |
|  |  |  |  |  |  |  |
| Total liabilities |  | 1,316,665 |  |  | 1,954,964 |  |
| Stockholders’ equity: |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| Common stock, $0.001 par value; 100,000,000 shares authorized; 32,501,709 and 31,977,953 shares issued, |  |  |  |  |  |  |
| respectively; 32,382,687 and 31,871,427 shares outstanding, respectively |  | 33 |  |  | 32 |  |
| Additional paid-in capital |  | 687,644 |  |  | 669,756 |  |
|  |  |  |  |  |  |  |
| Treasury stock, at cost, 119,022 and 106,526 shares, respectively |  | (5,668) |  |  | (4,654) |  |
| Retained earnings |  | 318,287 |  |  | 176,068 |  |
|  |  |  |  |  |  |  |
| Accumulated other comprehensive income |  | 39,035 |  |  | 52,179 |  |
| Total stockholders’ equity |  | 1,039,331 |  |  | 893,381 |  |
|  |  |  |  |  |  |  |
| Total liabilities and stockholders’ equity | $ | 2,355,996 |  | $ | 2,848,345 |  |
|  |  |  |  |  |  |  |

The accompanying notes are an integral part of these condensed consolidated financial statements.

- 3 -

**INTEGER HOLDINGS CORPORATION**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended** | | | | |  | **Nine Months Ended** | | | |
|  |  |  | |  |  |  |  |  | |  |  |
|  |  | **September 28,** | |  | **September 29,** | |  | **September 28,** | |  | **September 29,** |
| **(in thousands except per share data)** |  | **2018** |  |  | **2017** |  |  | **2018** |  |  | **2017** |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Sales | $ | 305,088 |  | $ | 286,168 |  | $ | 911,978 |  | $ | 833,820 |
| Cost of sales |  | 213,165 |  |  | 196,982 |  |  | 637,758 |  |  | 573,431 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Gross profit |  | 91,923 |  |  | 89,186 |  |  | 274,220 |  |  | 260,389 |
| Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Selling, general and administrative expenses |  | 34,091 |  |  | 35,064 |  |  | 107,300 |  |  | 105,004 |
| Research, development and engineering costs |  | 12,234 |  |  | 12,227 |  |  | 38,445 |  |  | 35,104 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Other operating expenses |  | 4,139 |  |  | 6,069 |  |  | 12,615 |  |  | 24,490 |
| Total operating expenses |  | 50,464 |  |  | 53,360 |  |  | 158,360 |  |  | 164,598 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Operating income |  | 41,459 |  |  | 35,826 |  |  | 115,860 |  |  | 95,791 |
| Interest expense |  | 54,526 |  |  | 15,808 |  |  | 85,355 |  |  | 49,233 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| (Gain) loss on cost and equity method investments, net |  | (291) |  |  | (1,906) |  |  | (5,545) |  |  | 2,919 |
| Other loss, net |  | 1,684 |  |  | 2,490 |  |  | 257 |  |  | 10,654 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Income (loss) from continuing operations before taxes |  | (14,460) |  |  | 19,434 |  |  | 35,793 |  |  | 32,985 |
| Provision (benefit) for income taxes |  | (6,157) |  |  | (448) |  |  | 7,956 |  |  | 596 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Income (loss) from continuing operations | $ | (8,303) |  | $ | 19,882 |  | $ | 27,837 |  | $ | 32,389 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Discontinued operations: |  |  |  |  |  |  |  |  |  |  |  |
| Income (loss) from discontinued operations before taxes |  | 195,874 |  |  | (7,444) |  |  | 188,251 |  |  | (21,074) |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Provision (benefit) for income taxes |  | 73,492 |  |  | (1,252) |  |  | 73,869 |  |  | (1,026) |
| Income (loss) from discontinued operations | $ | 122,382 |  | $ | (6,192) |  | $ | 114,382 |  | $ | (20,048) |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Net income | $ | 114,079 |  | $ | 13,690 |  | $ | 142,219 |  | $ | 12,341 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Basic earnings (loss) per share: |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Income (loss) from continuing operations | $ | (0.26) |  | $ | 0.63 |  | $ | 0.87 |  | $ | 1.03 |
| Income (loss) from discontinued operations |  | 3.80 |  |  | (0.20) |  |  | 3.57 |  |  | (0.64) |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Basic earnings per share |  | 3.54 |  |  | 0.43 |  |  | 4.44 |  |  | 0.39 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Diluted earnings (loss) per share: |  |  |  |  |  |  |  |  |  |  |  |
| Income (loss) from continuing operations | $ | (0.26) |  | $ | 0.62 |  | $ | 0.86 |  | $ | 1.01 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Income (loss) from discontinued operations |  | 3.80 |  |  | (0.19) |  |  | 3.52 |  |  | (0.63) |
| Diluted earnings per share |  | 3.54 |  |  | 0.43 |  |  | 4.38 |  |  | 0.39 |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Weighted average shares outstanding: |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Basic |  | 32,211 |  |  | 31,594 |  |  | 32,050 |  |  | 31,304 |
| Diluted |  | 32,211 |  |  | 32,173 |  |  | 32,451 |  |  | 31,947 |

The accompanying notes are an integral part of these condensed consolidated financial statements.

- 4 -

**INTEGER HOLDINGS CORPORATION**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended** | | | | |  | **Nine Months Ended** | | | |
|  |  |  | |  |  |  |  |  | |  |  |
|  |  | **September 28,** | |  | **September 29,** | |  | **September 28,** | |  | **September 29,** |
| **(in thousands)** |  | **2018** |  |  | **2017** |  |  | **2018** |  |  | **2017** |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Comprehensive Income** |  |  |  |  |  |  |  |  |  |  |  |
| Net income | $ | 114,079 |  | $ | 13,690 |  | $ | 142,219 |  | $ | 12,341 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Other comprehensive income (loss): |  |  |  |  |  |  |  |  |  |  |  |
| Foreign currency translation gain (loss) |  | (2,809) |  |  | 16,728 |  |  | (15,253) |  |  | 57,863 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Net change in cash flow hedges, net of tax |  | 634 |  |  | (339) |  |  | 1,957 |  |  | 1,729 |
| Other comprehensive income (loss) |  | (2,175) |  |  | 16,389 |  |  | (13,296) |  |  | 59,592 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Comprehensive income | $ | 111,904 |  | $ | 30,079 |  | $ | 128,923 |  | $ | 71,933 |
|  |  |  |  |  |  |  |  |  |  |  |  |

The accompanying notes are an integral part of these condensed consolidated financial statements.

- 5 -

**INTEGER HOLDINGS CORPORATION**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | **Nine Months Ended** | | | |
|  |  |  | |  |  |
|  |  | **September 28,** | |  | **September 29,** |
| **(in thousands)** |  | **2018** |  |  | **2017** |
|  |  |  |  |  |  |
| **Cash flows from operating activities:** |  |  |  |  |  |
| Net income | $ | 142,219 |  | $ | 12,341 |
|  |  |  |  |  |  |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |  |  |
| Depreciation and amortization |  | 68,447 |  |  | 74,584 |
|  |  |  |  |  |  |
| Debt related amortization and extinguishment fees included in interest expense |  | 47,173 |  |  | 8,850 |
| Stock-based compensation |  | 7,684 |  |  | 9,895 |
|  |  |  |  |  |  |
| Non-cash (gain) loss on cost and equity method investments |  | (1,043) |  |  | 3,833 |
| Other non-cash (gains) losses |  | (771) |  |  | 6,833 |
|  |  |  |  |  |  |
| Deferred income taxes |  | 66,953 |  |  | (6,821) |
| Gain on sale of discontinued operations |  | (194,734) |  |  | — |
|  |  |  |  |  |  |
| Changes in operating assets and liabilities: |  |  |  |  |  |
| Accounts receivable |  | (4,805) |  |  | (13,958) |
|  |  |  |  |  |  |
| Inventories |  | (19,688) |  |  | (20,259) |
| Prepaid expenses and other current assets |  | 5,155 |  |  | 8,460 |
|  |  |  |  |  |  |
| Accounts payable |  | 10,488 |  |  | 12,905 |
| Accrued expenses |  | (14,904) |  |  | 4,191 |
|  |  |  |  |  |  |
| Income taxes |  | 8,562 |  |  | 14,716 |
| Net cash provided by operating activities |  | 120,736 |  |  | 115,570 |
|  |  |  |  |  |  |
| **Cash flows from investing activities:** |  |  |  |  |  |
| Acquisition of property, plant and equipment |  | (33,340) |  |  | (34,059) |
|  |  |  |  |  |  |
| Proceeds from sale of property, plant and equipment |  | 1,366 |  |  | 464 |
| Purchase of cost and equity method investments |  | (1,230) |  |  | (1,316) |
|  |  |  |  |  |  |
| Proceeds from sale of discontinued operations |  | 582,359 |  |  | — |
| Other investing activities |  | — | |  | 209 |
|  |  |  |  |  |  |
| Net cash provided by (used in) investing activities |  | 549,155 |  |  | (34,702) |
| **Cash flows from financing activities:** |  |  |  |  |  |
|  |  |  |  |  |  |
| Principal payments of long-term debt |  | (670,094) |  |  | (156,526) |
| Proceeds from issuance of long-term debt |  | — | |  | 50,000 |
|  |  |  |  |  |  |
| Proceeds from the exercise of stock options |  | 11,757 |  |  | 17,074 |
| Payment of debt issuance and redemption costs |  | (31,991) |  |  | (1,789) |
|  |  |  |  |  |  |
| Tax withholdings related to net share settlements of restricted stock unit awards |  | (2,568) |  |  | (76) |
| Net cash used in financing activities |  | (692,896) |  |  | (91,317) |
|  |  |  |  |  |  |
| Effect of foreign currency exchange rates on cash and cash equivalents |  | 1,790 |  |  | 1,970 |
| Net decrease in cash and cash equivalents |  | (21,215) |  |  | (8,479) |
|  |  |  |  |  |  |
| Cash and cash equivalents, beginning of period |  | 44,096 |  |  | 52,116 |
| Cash and cash equivalents, end of period | $ | 22,881 |  | $ | 43,637 |
| **Supplemental disclosure of cash flow information(1):** |  |  |  |  |  |
| Noncash investing and financing activities: |  |  |  |  |  |
|  |  |  |  |  |  |
| Property, plant and equipment purchases included in accounts payable | $ | 2,585 |  | $ | 6,406 |
|  |  |  |  |  |  |

1. Refer to Note 2 “Discontinued Operations and Divestiture” for additional supplemental cash flow information pertaining to discontinued operations. The accompanying notes are an integral part of these condensed consolidated financial statements.
   * 6 -

**INTEGER HOLDINGS CORPORATION**

**CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (Unaudited)**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Common Stock** | | | | |  |  |  | **Treasury Stock** | | | | |  |  |  |  | **Accumulated** | |  |  |  |
|  |  | **Additional** | |  |  |  |  | **Other** | |  | **Total** |  |
|  |  |  |  |  |  |  | **Paid-In** | |  |  |  |  |  |  | **Retained** | |  | **Comprehensive** | |  | **Stockholders’** |  |
| **(in thousands)** | **Shares** | |  | **Amount** | |  | **Capital** | | **Shares** | |  | **Amount** | |  | **Earnings** | |  | **Income** | |  | **Equity** |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **December 29, 2017** | **31,978** |  | **$** | **32** |  | **$** | **669,756** |  | **(107)** |  | **$** | **(4,654)** |  | **$** | **176,068** |  | **$** | **52,179** |  | **$** | **893,381** |  |
| Comprehensive income: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Net income | — | |  | — | |  | — | | — | |  | — | |  | 142,219 |  |  | — | |  | 142,219 |  |
| Other comprehensive loss, net | — | |  | — | |  | — | | — | |  | — | |  | — | |  | (13,296) |  |  | (13,296) |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Accumulated other comprehensive income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| reclassified to earnings, net | — | |  | — | |  | — | | — | |  | — | |  | — | |  | 152 |  |  | 152 |  |
| Share-based compensation plans: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Stock-based compensation | — | |  | — | |  | 7,684 |  | — | |  | — | |  | — | |  | — | |  | 7,684 |  |
| Net shares issued | 524 |  |  | 1 |  |  | 10,204 |  | (12) |  |  | (1,014) |  |  | — | |  | — | |  | 9,191 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **September 28, 2018** | **32,502** |  | **$** | **33** |  | **$** | **687,644** |  | **(119)** |  | **$** | **(5,668)** |  | **$** | **318,287** |  | **$** | **39,035** |  | **$** | **1,039,331** |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

The accompanying notes are an integral part of these condensed consolidated financial statements.

- 7 -

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(1.)** **BASIS OF PRESENTATION**

Integer Holdings Corporation (together with its consolidated subsidiaries, “Integer” or the “Company”) is a publicly traded corporation listed on the New York Stock Exchange under the symbol “ITGR.” Integer is one of the largest medical device outsource manufacturers in the world serving the cardiac, neuromodulation, vascular and portable medical markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in the energy, military, and environmental markets. The Company’s reportable segments are: (1) Medical and (2) Non-Medical. The Company’s customers include large multi-national original equipment manufacturers (“OEMs”) and their affiliated subsidiaries.

On May 3, 2018, the Company entered into a definitive agreement to sell the Advanced Surgical and Orthopedic product lines (the “AS&O Product Line”) within its Medical segment to Viant (formerly MedPlast, LLC), and on July 2, 2018 completed the sale. The results of operations of the AS&O Product Line are reported as discontinued operations in the Condensed Consolidated Statements of Operations for all periods presented and the related assets and liabilities associated with the discontinued operations are classified as held for sale in the Condensed Consolidated Balance Sheet as of December 29, 2017. The Condensed Consolidated Statements of Cash Flows includes cash flows related to the discontinued operations due to Integer’s (parent) centralized treasury and cash management processes, and, accordingly, cash flow amounts for discontinued operations are disclosed in Note 2 “Discontinued Operations and Divestiture.” The Condensed Consolidated Balance Sheet as of December 29, 2017 was derived from the Company’s audited financial statements and has been retrospectively adjusted to reflect discontinued operations. All results and information in the condensed consolidated financial statements are presented as continuing operations and exclude the AS&O Product Line unless otherwise noted specifically as discontinued operations. Refer to Note 2 “Discontinued Operations and Divestiture” for additional information.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, *Interim Reporting*) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented. Intercompany transactions and balances have been fully eliminated in consolidation.

Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, certain components of equity, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates. For further information, refer to the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 29, 2017.

The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. The third quarter of 2018 and 2017 each contained 13 weeks and ended on September 28 and September 29, respectively. The Company’s 2018 and 2017 fiscal years will end or ended on December 28, 2018 and December 29, 2017, respectively.

- 8 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(2.) DISCONTINUED OPERATIONS AND DIVESTITURE**

On May 3, 2018, the Company entered into a definitive agreement to sell its AS&O Product Line to Viant, and on July 2, 2018, completed the sale, collecting cash proceeds of approximately $582 million, which is net of transaction costs and adjustments set forth in the definitive agreement. In connection with the sale, the parties executed a transition services agreement whereby the Company will provide certain corporate services (including accounting, payroll, and information technology services) to Viant for a period of up to one year from the date of the closing to facilitate an orderly transfer of business operations. Viant will pay Integer for these services, with such payments varying in amount and length of time as specified in the transition services agreement. The Company recognized $1.9 million of income under the transition services agreement for the performance of services during the third quarter of fiscal 2018, of which $0.1 million is within Cost of sales and $1.8 million is within Selling, general and administrative expenses. In addition, the parties executed long-term supply agreements under which the Company and Viant have agreed to supply the other with certain products at prices specified in the agreements for a term of three years.

In connection with the closing of the transaction, the Company recognized a pre-tax gain on sale of discontinued operations of $194.7 million. The Company is in the process of finalizing the net working capital adjustment with Viant as provided for in the definitive agreement. The final net working capital adjustment, as determined through the established process outlined in the definitive agreement, may be different from the Company’s estimates. The impact of any changes in the net working capital adjustment will be recorded as an adjustment to the gain on sale from discontinued operations in the period such change occurs. Additionally, the income taxes associated with the gain will be impacted by the final allocation of the sales price, which must be agreed to with Viant as required in the definitive agreement and may be materially different from the Company’s estimates. The impact of any changes in estimated income taxes will be recorded as an adjustment to discontinued operations in the period such change in estimate occurs.

The operating results of the AS&O Product Line have been classified as discontinued operations in the Condensed Consolidated Statements of Operations for all periods presented and the assets and liabilities of the AS&O Product Line have been classified as assets and liabilities of discontinued operations in the Condensed Consolidated Balance Sheet at December 29, 2017. The discontinued operations of the AS&O Product Line are reported in the Medical segment.

The assets and liabilities of a discontinued operation held for sale, other than goodwill, are measured at the lower of carrying amount or fair value less cost to sell. Accordingly, the assets and liabilities of the AS&O Product Line, other than goodwill, are measured at carrying amount. ASC 350, *Intangibles —* *Goodwill and Other*, states that when a portion of a goodwill reporting unit that constitutes a business is to be disposed of, goodwill associated with thatbusiness shall be included in the carrying amount of the business based on the relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained. As the AS&O Product Line was a portion of the Medical goodwill reporting unit, and management determined it met the definition of a business, goodwill was allocated to the AS&O Product Line on a relative fair value basis, as prescribed by ASC 350. The fair value of the AS&O Product Line assets was based primarily on the initial purchase price of $600 million.

- 9 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(2.)** **DISCONTINUED OPERATIONS AND DIVESTITURE (Continued)**

The carrying amounts of the AS&O Product Line assets and liabilities that were classified as assets and liabilities of discontinued operations held for sale were as follows (in thousands):

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  | **December 29,** |  |
|  |  |  |  |  |  |  |  |  |  |  | **2017** |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Cash and cash equivalents |  |  |  |  |  |  |  |  |  | $ | 6,755 |  |
|  | | |  |  |  |  |  |  |  |  |  |  |
| Accounts receivable, net of allowance for doubtful accounts of $0.3 million | | | |  |  |  |  |  |  |  | 47,611 |  |
| Inventories |  |  |  |  |  |  |  |  |  |  | 50,796 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Prepaid expenses and other current assets |  |  |  |  |  |  |  |  |  |  | 1,584 |  |
| Current assets of discontinued operations held for sale |  |  |  |  |  |  |  |  |  |  | 106,746 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Property, plant and equipment, net |  |  |  |  |  |  |  |  |  |  | 135,195 |  |
| Goodwill |  |  |  |  |  |  |  |  |  |  | 150,368 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Other intangible assets, net |  |  |  |  |  |  |  |  |  |  | 57,520 |  |
| Other noncurrent assets |  |  |  |  |  |  |  |  |  |  | 1,551 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Noncurrent assets of discontinued operations held for sale |  |  |  |  |  |  |  |  |  |  | 344,634 |  |
| Total assets |  |  |  |  |  |  |  |  |  |  | 451,380 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Accounts payable and other current liabilities held for sale |  |  |  |  |  |  |  |  |  |  | 47,703 |  |
| Deferred taxes and other long-term liabilities held for sale |  |  |  |  |  |  |  |  |  |  | 14,966 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Total liabilities |  |  |  |  |  |  |  |  |  |  | 62,669 |  |
| Net assets |  |  |  |  |  |  |  |  |  | $ | 388,711 |  |
| Income (loss) from discontinued operations, net of taxes, were as follows (in thousands): | | | |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  | **Three Months Ended** | | | | |  | **Nine Months Ended** | | | |  |
|  |  |  | |  |  |  |  |  | |  |  |  |
|  |  | **September 28,** | |  | **September 29,** | |  | **September 28,** | |  | **September 29,** |  |
|  |  | **2018** |  |  | **2017** |  |  | **2018** |  |  | **2017** |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Sales | $ | — | | $ | 77,140 |  | $ | 178,020 |  | $ | 237,620 |  |
| Cost of sales |  | — | |  | 68,091 |  |  | 148,357 |  |  | 209,276 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Gross profit |  | — | |  | 9,049 |  |  | 29,663 |  |  | 28,344 |  |
| Selling, general and administrative expenses |  | — | |  | 4,669 |  |  | 8,905 |  |  | 13,952 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Research, development and engineering costs |  | — | |  | 1,380 |  |  | 2,352 |  |  | 4,803 |  |
| Other operating expenses (income)(1) |  | (2,185) |  |  | 195 |  |  | 1,805 |  |  | 465 |  |
| Interest expense |  | 976 |  |  | 10,677 |  |  | 22,833 |  |  | 31,792 |  |
| Gain on sale of discontinued operations |  | (194,734) |  |  | — | |  | (194,734) |  |  | — |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Other (income) loss, net |  | 69 |  |  | (428) |  |  | 251 |  |  | (1,594) |  |
| Income (loss) from discontinued operations |  |  |  |  |  |  |  |  |  |  |  |  |
| before taxes |  | 195,874 |  |  | (7,444) |  |  | 188,251 |  |  | (21,074) |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Provision (benefit) for income taxes |  | 73,492 |  |  | (1,252) |  |  | 73,869 |  |  | (1,026) |  |
| Income (loss) from discontinued operations | $ | 122,382 |  | $ | (6,192) |  | $ | 114,382 |  | $ | (20,048) |  |
| \_\_\_\_\_\_\_\_\_\_ |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |

1. The Company recorded $2.2 million of transaction costs in Other operating expenses (income) from discontinued operations during the three months ended June 29, 2018, which were reclassified to the Gain on sale of discontinued operations during the three months ended September 28, 2018.
   * 10 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(2.)** **DISCONTINUED OPERATIONS AND DIVESTITURE (Continued)**

The Company allocates interest to discontinued operations if the interest is directly attributable to the discontinued operations or is interest on debt that is required to be repaid as a result of the disposal transaction. Interest expense included in discontinued operations reflects an estimate of interest expense related to the debt that was required to be repaid with the proceeds from the sale of the AS&O Product Line.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash flow information from discontinued operations was as follows (in thousands): | |  |  |  |  |  |  |  |  |
|  |  |  | **Nine Months Ended** | | | | | |  |
|  |  |  |  | |  |  |  |  |  |
|  |  |  | **September 28,** | | |  |  | **September 29,** |  |
|  |  |  | **2018** |  |  |  |  | **2017** |  |
|  |  |  |  |  |  |  |  |  |  |
|  | Cash used in operating activities | $ | (12,388) |  |  | $ | | (2,580) |  |
|  | Cash provided by (used in) investing activities |  | 578,763 |  |  |  |  | (11,659) |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  | Depreciation and amortization | $ | 7,450 |  |  | $ | | 15,947 |  |
|  |  |  |  |  |  |  |  |  |  |
|  | Capital expenditures |  | 3,610 |  |  |  |  | 11,732 |  |
| **(3.) INVENTORIES** | |  |  |  |  |  |  |  |  |
| Inventories are comprised of the following (in thousands): | |  |  |  |  |  |  |  |  |
|  |  |  | **September 28,** | | |  |  | **December 29,** |  |
|  |  |  | **2018** |  |  |  |  | **2017** |  |
|  | |  |  |  |  |  |  |  |  |
| Raw materials | | $ | 81,443 |  |  | $ | | 85,050 |  |
| Work-in-process | |  | 78,966 |  |  |  |  | 63,620 |  |
|  | |  |  |  |  |  |  |  |  |
| Finished goods | |  | 33,222 |  |  |  |  | 28,068 |  |
|  | Total | $ | 193,631 |  |  |  | $ | 176,738 |  |
|  |  |  |  |  |  |  |  |  |  |

Refer to Note 2 “Discontinued Operations and Divestiture” for inventories included in discontinued operations, which are not included above.

- 11 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(4.) GOODWILL AND OTHER INTANGIBLE ASSETS, NET**

**Goodwill**

The changes in the carrying amount of goodwill by reportable segment for the nine months ended September 28, 2018 were as follows (in thousands):

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Medical** | |  | **Non- Medical** | |  | **Total** |
|  |  |  |  |  |  |  |  |  |
| December 29, 2017 | $ | 822,870 |  | $ | 17,000 |  | $ | 839,870 |
| Foreign currency translation |  | (5,350) |  |  | — | |  | (5,350) |
|  |  |  |  |  |  |  |  |  |
| September 28, 2018 | $ | 817,520 |  | $ | 17,000 |  | $ | 834,520 |
|  |  |  |  |  |  |  |  |  |

**Intangible Assets**

Intangible assets at September 28, 2018 and December 29, 2017 were as follows (in thousands):

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Gross** | |  |  |  |  | **Net** |  |
|  |  | **Carrying** | |  | **Accumulated** | |  | **Carrying** |  |
|  |  | **Amount** | |  | **Amortization** | |  | **Amount** |  |
|  |  |  |  |  |  |  |  |  |  |
| **September 28, 2018** |  |  |  |  |  |  |  |  |  |
| ***Definite-lived:*** |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
| Purchased technology and patents | $ | 242,292 |  | $ | (121,743) |  | $ | 120,549 |  |
| Customer lists |  | 712,795 |  |  | (98,299) |  |  | 614,496 |  |
|  |  |  |  |  |  |  |  |  |  |
| Other |  | 3,503 |  |  | (3,477) |  |  | 26 |  |
| Total | $ | 958,590 |  | $ | (223,519) |  | $ | 735,071 |  |
| ***Indefinite-lived:*** |  |  |  |  |  |  |  |  |  |
| Trademarks and tradenames |  |  |  |  |  |  | $ | 90,288 |  |
|  |  |  |  |  |  |  |  |  |  |
| **December 29, 2017** |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
| ***Definite-lived:*** |  |  |  |  |  |  |  |  |  |
| Purchased technology and patents | $ | 243,679 |  | $ | (111,185) |  | $ | 132,494 |  |
|  |  |  |  |  |  |  |  |  |  |
| Customer lists |  | 718,649 |  |  | (78,621) |  |  | 640,028 |  |
| Other |  | 4,660 |  |  | (4,597) |  |  | 63 |  |
|  |  |  |  |  |  |  |  |  |  |
| Total | $ | 966,988 |  | $ | (194,403) |  | $ | 772,585 |  |
| ***Indefinite-lived:*** |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
| Trademarks and tradenames |  |  |  |  |  |  | $ | 90,288 |  |
|  |  |  |  |  |  |  |  |  |  |

Aggregate intangible asset amortization expense is comprised of the following (in thousands):

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended** | | | | |  | **Nine Months Ended** | | | |
|  |  |  | |  |  |  |  |  | |  |  |
|  |  | **September 28,** | |  | **September 29,** | |  | **September 28,** | |  | **September 29,** |
|  |  | **2018** |  |  | **2017** |  |  | **2018** |  |  | **2017** |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Cost of sales | $ | 3,367 |  | $ | 3,786 |  | $ | 10,756 |  | $ | 11,282 |
| Selling, general and administrative expenses |  | 6,490 |  |  | 6,222 |  |  | 20,196 |  |  | 18,684 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Research, development and engineering costs |  | 39 |  |  | 137 |  |  | 116 |  |  | 409 |
| Total intangible asset amortization expense | $ | 9,896 |  | $ | 10,145 |  | $ | 31,068 |  | $ | 30,375 |
|  |  |  |  |  |  |  |  |  |  |  |  |

Estimated future intangible asset amortization expense based on the carrying value as of September 28, 2018 is as follows (in thousands):

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **2018** |  |  | **2019** |  |  | **2020** |  |  | **2021** |  |  | **2022** |  | **After 2022** |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Amortization Expense | $ | 9,918 |  | $ | 40,491 |  | $ | 40,804 |  | $ | 39,948 |  | $ | 38,807 | $ | 565,103 |
|  |  |  |  |  | - 12 - |  |  |  |  |  |  |  |  |  |  |  |

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **(5.) DEBT** |  |  |  |  |  |
| Long-term debt is comprised of the following (in thousands): |  |  |  |  |  |
|  |  | **September 28,** | |  | **December 29,** |
|  |  | **2018** |  |  | **2017** |
|  |  |  |  |  |  |
| Senior secured term loan A | $ | 314,063 |  | $ | 335,157 |
| Senior secured term loan B |  | 658,286 |  |  | 873,286 |
|  |  |  |  |  |  |
| 9.125% senior notes due 2023 |  | — | |  | 360,000 |
| Revolving line of credit |  | — | |  | 74,000 |
|  |  |  |  |  |  |
| Unamortized discount on term loan B and debt issuance costs |  | (18,155) |  |  | (33,278) |
| Total debt |  | 954,194 |  |  | 1,609,165 |
|  |  |  |  |  |  |
| Current portion of long-term debt |  | (37,500) |  |  | (30,469) |
| Total long-term debt | $ | 916,694 |  | $ | 1,578,696 |
|  |  |  |  |  |  |

**Senior Secured Credit Facilities**

The Company has senior secured credit facilities (the “Senior Secured Credit Facilities”) consisting of (i) a $200 million revolving credit facility (the “Revolving Credit Facility”), (ii) a $314 million term loan A facility (the “TLA Facility”), and (iii) a $658 million term loan B facility (the “TLB Facility”). The TLA Facility and TLB Facility are collectively referred to as the “Term Loan Facilities.” The TLB Facility was issued at a 1% discount.

On June 8, 2018, the Company amended the Senior Secured Credit Facilities to permit the sale of the AS&O Product Line. As required by the amended terms of the Company’s Senior Secured Credit Facilities, the Company paid down indebtedness as a result of the disposition of the AS&O Product Line. On July 10, 2018, the Company completed the redemption in full of its 9.125% senior notes due on November 1, 2023 (the “Senior Notes”) at a redemption price of 100% of the principal amount of the Senior Notes plus the applicable “make-whole” premium of $31.3 million and accrued and unpaid interest through the redemption date. Upon completion of the redemption of the Senior Notes, the indenture governing the Senior Notes was satisfied and discharged. The Company utilized the remaining net proceeds to pay down an additional $188 million in debt outstanding under the Senior Secured Credit Facilities, consisting of $114 million on the TLB Facility and $74 million on the Revolving Credit Facility.

***Revolving Credit Facility***

The Revolving Credit Facility matures on October 27, 2020. The Revolving Credit Facility also includes a $15 million sublimit for swingline loans and a $25 million sublimit for standby letters of credit. The Company is required to pay a commitment fee on the unused portion of the Revolving Credit Facility, which will range between 0.175% and 0.25%, depending on the Company’s Total Net Leverage Ratio (as defined in the Senior Secured Credit Facilities agreement). Interest rates on the Revolving Credit Facility, as well as the TLA Facility, are at the Company’s option, either at: (i) the prime rate plus the applicable margin, which will range between 0.75% and 2.25%, based on the Company’s Total Net Leverage Ratio, or (ii) the applicable LIBOR rate plus the applicable margin, which will range between 1.75% and 3.25%, based on the Company’s Total Net Leverage Ratio.

As of September 28, 2018, the Company had no outstanding borrowings on the Revolving Credit Facility and an available borrowing capacity of $191.3 million after giving effect to $8.7 million of outstanding standby letters of credit.

Subject to certain conditions, commitments under the Revolving Credit Facility may be increased through an incremental revolving facility so long as, on a pro forma basis, the Company’s first lien net leverage ratio does not exceed 4.25:1.00. Due to being variable rate and short-term in nature, the carrying amount of the Revolving Credit Facility approximates fair value.

- 13 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(5.)** **DEBT (Continued)**

***Term Loan Facilities***

The TLA Facility and TLB Facility mature on October 27, 2021 and October 27, 2022, respectively. As a result of the upgrade to the Company’s corporate family credit rating from Moody’s Investors Services, Inc. from B3 to B2 during the third quarter of 2018, the interest rate margin for the TLB Facility was stepped down by 25 basis points. Interest rates on the TLB Facility are, at the Company’s option, either at: (i) the prime rate plus 2.00% or (ii) the applicable LIBOR rate plus 3.00%, with LIBOR subject to a 1.00% floor. As of September 28, 2018, the interest rates on the TLA Facility and TLB Facility were 4.74% and 5.14%, respectively.

Subject to certain conditions, one or more incremental term loan facilities may be added to the Term Loan Facilities so long as, on a pro forma basis, the Company’s first lien net leverage ratio does not exceed 4.25:1.00.

As of September 28, 2018, the estimated fair value of the TLB Facility was approximately $664 million, based on quoted market prices for the debt, recent sales prices for the debt and consideration of comparable debt instruments with similar interest rates and trading frequency, among other factors, and is classified as Level 2 measurements within the fair value hierarchy. The par amount of the TLA Facility approximated its fair value as of September 28, 2018 based upon the debt being variable rate in nature.

***Covenants***

The Revolving Credit Facility and TLA Facility contain covenants requiring (A) a maximum Total Net Leverage Ratio of 5.75:1.00, subject to periodic step downs in beginning in the fourth quarter of 2018 and (B) a minimum interest coverage ratio of adjusted EBITDA (as defined in the Senior Secured Credit Facilities) to interest expense of not less than 2.75:1.00 subject to a step up beginning in the first quarter of 2019. As of September 28, 2018, the Company was in compliance with these financial covenants. The TLB Facility does not contain any financial maintenance covenants.

The Senior Secured Credit Facilities also contain negative covenants that restrict the Company’s ability to (i) incur additional indebtedness; (ii) create certain liens; (iii) consolidate or merge; (iv) sell assets, including capital stock of the Company’s subsidiaries; (v) engage in transactions with the Company’s affiliates; (vi) create restrictions on the payment of dividends or other amounts from the Company’s restricted subsidiaries; (vii) pay dividends on capital stock or redeem, repurchase or retire capital stock; (viii) pay, prepay, repurchase or retire certain subordinated indebtedness; (ix) make investments, loans, advances and acquisitions; (x) make certain amendments or modifications to the organizational documents of the Company or its subsidiaries or the documentation governing other senior indebtedness of the Company; and (xi) change the Company’s type of business. These negative covenants are subject to a number of limitations and exceptions that are described in the Senior Secured Credit Facilities agreement. As of September 28, 2018, the Company was in compliance with all negative covenants under the Senior Secured Credit Facilities.

The Senior Secured Credit Facilities provide for customary events of default. Upon the occurrence and during the continuance of an event of default, the outstanding advances and all other obligations under the Senior Secured Credit Facilities become immediately due and payable.

**9.125% Senior Notes due 2023**

On October 27, 2015, the Company completed a private offering of $360 million aggregate principal amount of 9.125% senior notes due on November 1, 2023 . On July 10, 2018, the Company completed the redemption in full of the Senior Notes at a redemption price of 100% of the principal amount of the Senior Notes plus the applicable “make-whole” premium of $31.3 million and accrued and unpaid interest through the redemption date. The “make-whole” premium is included in Interest Expense in the accompanying Condensed Consolidated Statements of Operations. Upon completion of the redemption of the Senior Notes, the indenture governing the Senior Notes was satisfied and discharged.

Contractual maturities under the Senior Secured Credit Facilities for the remainder of 2018 and the next four years and thereafter, excluding any discounts or premiums, as of September 28, 2018 are as follows (in thousands):

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **2018** |  |  | **2019** |  |  | **2020** |  |  | **2021** |  |  | **2022** |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Future minimum principal payments | $ | 9,375 |  | $ | 37,500 |  | $ | 37,500 |  | $ | 229,688 |  | $ | 658,286 |
|  |  | - 14 - |  |  |  |  |  |  |  |  |  |  |  |  |

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

|  |  |  |
| --- | --- | --- |
| **(5.) DEBT (Continued)** |  |  |
| **Debt Issuance Costs and Discounts** |  |  |
| The change in deferred debt issuance costs related to the Revolving Credit Facility is as follows (in thousands): |  |  |
|  |  |  |
| December 29, 2017 | $ | 2,808 |
| Amortization during the period |  | (743) |
|  |  |  |
| September 28, 2018 | $ | 2,065 |
|  |  |  |

The change in unamortized discount and debt issuance costs related to the Term Loan Facilities and Senior Notes is as follows (in thousands):

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | **Unamortized** | |  |  |  |
|  |  | **Debt Issuance** | | **Discount on TLB** | | |  |  |  |
|  |  | **Costs** | |  | **Facility** | |  | **Total** |  |
|  |  |  |  |  |  |  |  |  |  |
| December 29, 2017 | $ | 26,889 |  | $ | 6,389 |  | $ | 33,278 |  |
| Write-off of debt issuance costs and unamortized discount(1) |  | (9,373) |  |  | (1,448) |  |  | (10,821) |  |
| Amortization during the period |  | (3,497) |  |  | (805) |  |  | (4,302) |  |
| September 28, 2018 | $ | 14,019 |  | $ | 4,136 |  | $ | 18,155 |  |
| \_\_\_\_\_\_\_\_\_\_ |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |

1. The Company redeemed its Senior Notes and prepaid portions of its TLB Facility during 2018 and 2017. The Company recognized losses from extinguishment of debt during the three and nine months ended September 28, 2018 of $9.3 million and $10.8 million, respectively. The Company recognized losses from extinguishment of debt during the three and nine months ended September 29, 2017 of $0.8 million and $3.3 million, respectively. The loss from extinguishment of debt represents the unamortized debt issuance costs related to the Senior Notes and the portion of the unamortized discount and debt issuance costs related to the portion of the TLB Facility that was prepaid and is included in Interest Expense in the accompanying Condensed Consolidated Statements of Operations.

**Interest Rate Swap**

During 2016, the Company entered into a three-year $200 million interest rate swap to hedge against potential changes in cash flows on the outstanding variable rate debt, which is indexed to the one-month LIBOR rate. The variable rate received on the interest rate swap and the variable rate paid on the outstanding debt will have the same rate of interest, excluding the credit spread, and will reset and pay interest on the same date. The swap is being accounted for as a cash flow hedge.

Information regarding the Company’s outstanding interest rate swap designated as a cash flow hedge as of September 28, 2018 is as follows (dollars in thousands):

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  | **Receive** | | |  |  |  |
|  |  |  |  |  |  |  |  | **Current** | | |  |  |  |
| **Notional** | |  |  |  |  | **Pay Fixed** | | **Floating** | | |  |  |  |
| **Amount** | | **Start Date** | | **End Date** | | **Rate** | | **Rate** | | | **Fair Value** | | **Balance Sheet Location** |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| $ 200,000 |  | Jun-17 | | Jun-20 | | 1.1325% |  | 2.2300% $ | | | 5,690 |  | Other Long-Term Assets |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |

The estimated fair value of the interest rate swap agreement represents the amount the Company would receive (pay) to terminate the contract. No portion of the change in fair value of the Company’s interest rate swap during the quarters ended September 28, 2018 and September 29, 2017 was considered ineffective. The amounts recorded to Interest Expense during the nine months ended September 28, 2018 and September 29, 2017 related to the Company’s interest rate swap were reductions of $1.1 million and $0.4 million, respectively. The estimated Accumulated Other Comprehensive Income related to the Company’s interest rate swaps that is expected to be reclassified into earnings within the next twelve months is a $2.9 million gain.

- 15 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(6.) BENEFIT PLANS**

The Company is required to provide its employees located in Switzerland and Mexico certain statutorily mandated defined benefits. The following tables set forth the components of the Company’s net periodic expense from continuing operations relating to retirement benefit plans (in thousands):

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended** | | | | |  | **Nine Months Ended** | | | |
|  |  |  | |  |  |  |  |  | |  |  |
|  |  | **September 28,** | |  | **September 29,** | |  | **September 28,** | |  | **September 29,** |
|  |  | **2018** |  |  | **2017** |  |  | **2018** |  |  | **2017** |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Service cost | $ | 54 |  | $ | 52 |  | $ | 162 |  | $ | 150 |
| Interest cost |  | 12 |  |  | 11 |  |  | 36 |  |  | 31 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Amortization of net loss |  | 8 |  |  | 11 |  |  | 25 |  |  | 34 |
| Expected return on plan assets |  | (4) |  |  | (4) |  |  | (13) |  |  | (14) |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Net defined benefit cost | $ | 70 |  | $ | 70 |  | $ | 210 |  | $ | 201 |
|  |  |  |  |  |  |  |  |  |  |  |  |

**(7.)** **STOCK-BASED COMPENSATION**

The Company maintains certain stock-based compensation plans that were approved by the Company’s stockholders and are administered by the Board of Directors, or the Compensation and Organization Committee of the Board. The stock-based compensation plans provide for the granting of stock options, shares of restricted stock awards (“RSAs”), restricted stock units (“RSUs”), stock appreciation rights and stock bonuses to employees, non-employee directors, consultants, and service providers.

The components and classification of stock-based compensation expense were as follows (in thousands):

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended** | | | | |  | **Nine Months Ended** | | | |
|  |  |  | |  |  |  |  |  | |  |  |
|  |  | **September 28,** | |  | **September 29,** | |  | **September 28,** | |  | **September 29,** |
|  |  | **2018** |  |  | **2017** |  |  | **2018** |  |  | **2017** |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Stock options | $ | 215 |  | $ | 325 |  | $ | 726 |  | $ | 1,303 |
| RSAs and RSUs (time-based) |  | 1,161 |  |  | 1,265 |  |  | 4,330 |  |  | 4,142 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Performance-based RSUs (“PSUs”) |  | 711 |  |  | 182 |  |  | 2,214 |  |  | 3,695 |
| Stock-based compensation expense |  |  |  |  |  |  |  |  |  |  |  |
| - continuing operations |  | 2,087 |  |  | 1,772 |  |  | 7,270 |  |  | 9,140 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Discontinued operations |  | (510) |  |  | 173 |  |  | 414 |  |  | 755 |
| Total stock-based compensation expense | $ | 1,577 |  | $ | 1,945 |  | $ | 7,684 |  | $ | 9,895 |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Cost of sales | $ | 222 |  | $ | 80 |  | $ | 598 |  | $ | 417 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Selling, general and administrative expenses |  | 1,821 |  |  | 1,839 |  |  | 6,568 |  |  | 6,332 |
| Research, development and engineering costs |  | 44 |  |  | 122 |  |  | 99 |  |  | 367 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Other operating expenses |  | — | |  | (269) |  |  | 5 |  |  | 2,024 |
| Discontinued operations |  | (510) |  |  | 173 |  |  | 414 |  |  | 755 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Total stock-based compensation expense | $ | 1,577 |  | $ | 1,945 |  | $ | 7,684 |  | $ | 9,895 |
|  |  |  |  |  |  |  |  |  |  |  |  |

During the first quarter of 2017, the Company recorded $2.2 million of accelerated stock-based compensation expense in connection with the transition of its former Chief Executive Officer per the terms of his contract, which was classified as Other Operating Expenses.

- 16 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **(7.) STOCK-BASED COMPENSATION (Continued)** |  |  |  |  |  |  |  |  |  |  |  |  |
| The weighted average fair value and assumptions used to value options granted are as follows: | | | |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  | **Nine Months Ended** | | | | | |
|  |  |  |  |  |  |  |  | |  |  |  |  |
|  |  |  |  |  |  |  | **September 28,** | | |  |  | **September 29,** |
|  |  |  |  |  |  |  | **2018** |  |  |  |  | **2017** |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Weighted average fair value |  |  |  | $ | | | 14.89 |  |  | $ | | 10.58 |
| Risk-free interest rate |  |  |  |  |  |  | 2.21% |  |  |  |  | 1.69% |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Expected volatility |  |  |  |  |  |  | 39% |  |  |  |  | 37% |
| Expected life (in years) |  |  |  |  |  |  | 4.0 |  |  |  |  | 4.1 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Expected dividend yield |  |  |  |  |  |  | —% | | |  |  | —% |
| The following table summarizes the Company’s stock option activity: |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  | **Weighted** | | |  |  |  |
|  |  |  |  |  |  |  | **Average** | | |  |  |  |
|  |  |  |  | **Weighted** | | | **Remaining** | | |  |  | **Aggregate** |
|  | **Number of** | |  | **Average** | | | **Contractual** | | |  |  | **Intrinsic** |
|  | **Stock** | |  | **Exercise** | | | **Life** | | |  |  | **Value** |
|  | **Options** | |  | **Price** | | | **(In Years)** | | |  |  | **(In Millions)** |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Outstanding at December 29, 2017 | 931,353 |  | $ | 30.89 |  |  |  |  |  |  |  |  |
| Granted | 28,447 |  |  | 45.13 |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Exercised | (381,793) |  |  | 30.80 |  |  |  |  |  |  |  |  |
| Forfeited or expired | (23,700) |  |  | 41.28 |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  | |  |  |  |  |
| Outstanding at September 28, 2018 | 554,307 |  | $ | 31.24 |  |  | 6.2 | |  | $ | | 28.7 |
|  |  |  |  |  |  |  |  | |  |  |  |  |
| Exercisable at September 28, 2018 | 433,487 |  | $ | 30.16 |  |  | 5.6 | |  | $ | | 22.9 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |

During the nine months ended September 28, 2018, the Company awarded grants of 0.3 million RSUs to certain members of management, of which 0.2 million are PSUs and the remainder are time-based RSUs that vest ratably over a period of three to four years. Of the PSUs, 0.1 million of the shares subject to each grant will be earned based upon achievement of specific Company performance metrics over a three-year performance period ending January 1, 2021, and 0.1 million of the shares subject to each grant will be earned based on the Company’s achievement of a relative total shareholder return (“TSR”) performance requirement, on a percentile basis, compared to a defined group of peer companies over a three-year performance period ending January 1, 2021. The number of PSUs earned based on the achievement of the Company performance metrics and TSR performance requirements, if any, will vest based on the recipient’s continuous service to the Company over a period of generally one to three years from the grant date. The time-based RSUs generally vest ratably over a three-year period.

The grant-date fair value of the TSR portion of the PSUs granted during the nine months ended September 28, 2018 was determined using the Monte Carlo simulation model on the date of grant, assuming the following (i) expected term of 2.92 years, (ii) risk free interest rate of 2.28%, (iii) expected dividend yield of 0.0% and (iv) expected stock price volatility over the expected term of the TSR award of 40%. The grant-date fair value of all other restricted stock awards is equal to the closing market price of Integer common stock on the date of grant.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| The following table summarizes RSA and RSU activity: |  |  |  |  |  |  |
|  |  | **Time-Vested** |  | **Weighted Average** | |  |
|  |  | **Activity** |  |  | **Fair Value** |  |
|  |  |  |  |  |  |  |
| Nonvested at December 29, 2017 | 163,431 | | $ | | 35.96 |  |
| Granted | 157,608 | |  |  | 50.76 |  |
|  |  |  |  |  |  |  |
| Vested | (28,197) | |  |  | 46.62 |  |
| Forfeited | (50,393) | |  |  | 41.97 |  |
|  |  |  |  |  |  |  |
| Nonvested at September 28, 2018 | 242,449 | | $ | | 43.09 |  |
|  | - 17 - |  |  |  |  |  |
|  |  |  |  |  |  |

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **(7.) STOCK-BASED COMPENSATION (Continued)** |  |  |  |  |
| The following table summarizes PSU activity: |  |  |  |  |
|  | **Performance-** |  |  | **Weighted** |
|  | **Vested** |  |  | **Average** |
|  | **Activity** |  |  | **Fair Value** |
|  |  |  |  |  |
| Nonvested at December 29, 2017 | 469,889 | $ | | 32.37 |
| Granted | 159,669 |  |  | 45.37 |
|  |  |  |  |  |
| Vested | (146,704) |  |  | 35.16 |
| Forfeited | (180,003) |  |  | 35.18 |
|  |  |  |  |  |
| Nonvested at September 28, 2018 | 302,851 | $ | | 36.20 |
|  |  |  |  |  |

**(8.)** **OTHER OPERATING EXPENSES**

Other Operating Expenses is comprised of the following (in thousands):

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended** | | | | |  | **Nine Months Ended** | | | |
|  |  |  | |  |  |  |  |  | |  |  |
|  |  | **September 28,** | |  | **September 29,** | |  | **September 28,** | |  | **September 29,** |
|  |  | **2018** |  |  | **2017** |  |  | **2018** |  |  | **2017** |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Strategic reorganization and alignment | $ | 2,643 |  | $ | — | | $ | 8,424 |  | $ | — |
| Manufacturing alignment to support growth |  | 877 |  |  | — | |  | 2,493 |  |  | — |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Consolidation and optimization initiatives |  | 137 |  |  | 2,979 |  |  | 698 |  |  | 8,055 |
| Acquisition and integration expenses |  | — | |  | 2,267 |  |  | — | |  | 10,057 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Asset dispositions, severance and other |  | 482 |  |  | 823 |  |  | 1,000 |  |  | 6,378 |
| Other operating expenses - continuing operations |  | 4,139 |  |  | 6,069 |  |  | 12,615 |  |  | 24,490 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Discontinued operations |  | (2,185) |  |  | 195 |  |  | 1,805 |  |  | 465 |
| Total other operating expenses | $ | 1,954 |  | $ | 6,264 |  | $ | 14,420 |  | $ | 24,955 |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |

**Strategic Reorganization and Alignment**

During the fourth quarter of 2017, the Company began to take steps to better align its resources in order to enhance the profitability of its portfolio of products. This includes improving its business processes and redirecting investments away from projects where the market does not justify the investment, as well as aligning resources with market conditions and the Company’s future strategic direction. The Company estimates that it will incur aggregate pre-tax charges in connection with the strategic reorganization and alignment plan, including projects reported in discontinued operations, of between approximately $28 million to $30 million, of which an estimated $16 million to $20 million are expected to result in cash outlays. During the nine months ended September 28, 2018, the Company incurred charges relating to this initiative which primarily included severance and personnel related costs for terminated employees and fees for professional services. These expenses were primarily recorded within the Medical segment. As of September 28, 2018, total expense incurred for this initiative since inception, including amounts reported in discontinued operations, was $16.0 million. These actions are expected to be substantially completed by the end of 2018.

**Manufacturing Alignment to Support Growth**

In 2017, the Company initiated several initiatives designed to reduce costs, improve operating efficiencies and increase manufacturing capacity to accommodate growth. The plan involves the relocation of certain manufacturing operations and expansion of certain of the Company's facilities. The Company estimates that it will incur aggregate pre-tax restructuring related charges in connection with the realignment plan of between approximately $9 million to $11 million, the majority of which are expected to be cash expenditures, and capital expenditures of between approximately $4 million to $6 million. Costs related to the Company’s manufacturing alignment to support growth initiative, were primarily recorded within the Medical segment. As of September 28, 2018, total expense incurred for this initiative since inception, including amounts reported in discontinued operations, was $2.8 million. These actions are expected to be substantially completed by the end of 2019.

- 18 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(8.)** **OTHER OPERATING EXPENSES (Continued)**

**Consolidation and Optimization Initiatives**

In 2014, the Company initiated plans to transfer certain manufacturing functions performed at its facility in Beaverton, OR to a new facility in Tijuana, Mexico. Additionally, during 2016, the Company announced it would be closing its facility in Clarence, NY after transferring the machined component product lines manufactured in that facility to other Integer locations in the U.S. Costs related to the Company’s consolidation and optimization initiatives were primarily recorded within the Medical segment. The Company does not expect to incur any material additional costs associated with these activities as these activities are substantially complete.

The following table summarizes the change in accrued liabilities related to the initiatives described above (in thousands):

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Severance and** | |  |  |  |  |  |
|  |  | **Retention** | |  | **Other** | |  | **Total** |
|  |  |  |  |  |  |  |  |  |
| December 29, 2017 | $ | 1,308 |  | $ | — | | $ | 1,308 |
| Restructuring charges |  | 5,347 |  |  | 6,268 |  |  | 11,615 |
|  |  |  |  |  |  |  |  |  |
| Cash payments |  | (5,438) |  |  | (5,981) |  |  | (11,419) |
| September 28, 2018 | $ | 1,217 |  | $ | 287 |  | $ | 1,504 |
|  |  |  |  |  |  |  |  |  |

**Acquisition and Integration Expenses**

The Company did not incur any additional costs associated with these activities during the nine months ended September 28, 2018. During the three and nine months ended September 29, 2017, the Company incurred $2.3 million and $10.1 million in acquisition and integration costs related to the acquisition of Lake Region Medical, consisting primarily of integration costs. Integration costs primarily include professional, consulting, severance, retention, relocation, and travel costs. The $0.4 million of acquisition and integration costs accrued as of December 29, 2017 were paid during the first quarter of 2018. These projects were completed as of December 29, 2017.

**Asset Dispositions, Severance and Other**

During the first nine months of 2018 and 2017, the Company recorded losses in connection with various asset disposals and/or write-downs. The 2017 amount also includes approximately $5.3 million in expense related to the Company’s leadership transitions, which were recorded within the corporate unallocated segment.

**(9.) INCOME TAXES**

The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including discrete items, changes in the mix and amount of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations.

On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Tax Reform Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of cumulative foreign earnings as of December 31, 2017.

- 19 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(9.)** **INCOME TAXES (Continued)**

Under GAAP, the effect of a change in tax laws or rates to be recognized in income from continuing operations for the period that includes the enactment date. As such, the Company recognized an estimate of the impact of the Tax Reform Act in the year ended December 29, 2017. The Company had an estimated $147.5 million of undistributed foreign earnings and profit subject to the deemed mandatory repatriation as of December 29, 2017 and recognized a provisional $14.7 million in 2017 for the one-time transition tax. The Company has sufficient U.S. net operating losses to offset cash tax liabilities associated with the repatriation tax. In addition, as a result of the reduction in the U.S. corporate income tax rate from 35% to 21% under the Tax Reform Act, the Company revalued its ending net deferred tax liabilities at December 29, 2017 and recognized a $56.5 million tax benefit in the Company’s Consolidated Statement of Operations for the year ended December 29, 2017. For further discussion of the impact of the Tax Reform Act for the year ended December 29, 2017, reference is made to Note 12 of the Company’s consolidated financial statements as of and for the year ended December 29, 2017 included in the Company’s 2017 Annual Report on Form 10-K for the year ended December 29, 2017.

On December 22, 2017, the Securities and Exchange Commission issued Staff Accounting Bulletin (“SAB”) No. 118 to address the application of GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Reform Act. The Company recognized the tax impact of the revaluation of deferred tax assets and liabilities and the provisional tax impact related to deemed repatriated earnings and included these amounts in its consolidated financial statements for the year ended December 29, 2017.

Based on additional analysis conducted, the Company updated the provisional amount of the one-time transition tax to $18.9 million, representing an increase of $4.2 million over the $14.7 million amount recorded as of December 29, 2017. The Company believes the remeasurement of its 2017 provisional amount is complete. As stated above, the Company has sufficient U.S. net operating losses to offset cash tax liabilities associated with the repatriation tax. In part, due to the utilization of additional net operating losses to offset the additional transition tax, the Company adjusted its revaluation of the adjusted ending net deferred tax liabilities as of December 29, 2017, resulting in a recognized tax benefit of $60.7 million, representing an increase of $4.2 million to the originally recorded $56.5 million tax benefit recorded in the Company’s Consolidated Statement of Operations for the year ended December 29, 2017. The impact of these adjustments has been reflected in the Company’s financial results for the three month period ended September 28, 2018 and its timely filed 2017 U.S. corporate income tax return.

In addition to the reduction of the U.S. federal corporate tax rate and the one-time transition tax discussed above, the Tax Reform Act also established new tax laws that affect 2018, including, but not limited to: (i) a general elimination of U.S. federal income taxes on dividends from foreign subsidiaries; (ii) a new U.S. income inclusion on certain earnings of foreign subsidiaries (Global Intangible Low-Taxed Income (“GILTI”)); (iii) the repeal of the domestic production activity deductions; (iv) limitations on the deductibility of certain executive compensation; (v) an elimination of the deduction for certain deemed “base erosion payments” made to foreign affiliates (Base Erosion and Anti-Abuse Tax (“BEAT”)); and (vi) a new provision that allows a domestic corporation an immediate deduction for a portion of its foreign derived intangible income (“FDII”).

The GILTI provisions require the Company to include foreign subsidiary earnings in excess of a deemed return on the foreign subsidiary’s tangible assets in its U.S. income tax return. The Company expects that it will be subject to incremental U.S. tax on GILTI income beginning in 2018. Because of the complexity of the new GILTI tax rules and the ongoing regulatory interpretation of the GILTI provisions, the Company is continuing its evaluation of this provision of the Tax Reform Act and the application of ASC 740, *Income Taxes*. Under GAAP, the Company is allowed to make an accounting policy choice of either (1) treating taxes due on future U.S. inclusions in taxable income related to GILTI as a current period expense when incurred (the “period cost method”) or (2) factoring such amounts into the Company's measurement of its deferred taxes (the “deferred method”). The Company's selection of an accounting policy with respect to the new GILTI tax rules will depend, in part, on analyzing its global income to determine whether it expects to have future U.S. inclusions in taxable income related to GILTI and, if so, what the impact is expected to be. Whether the Company expects to have future U.S. inclusions in taxable income related to GILTI depends on not only the Company's current structure and estimated future results of global operations, but also its intent and ability to modify its structure. While the Company has included an estimate of GILTI in its estimated effective tax rate for 2018, it has not finalized its analysis and is not yet able to determine which method to elect. Adjustments related to the amount of GILTI Tax recorded in its condensed consolidated financial statements may be required based on the outcome of this election.

The BEAT provisions in the Tax Reform Act eliminate the deduction of certain base-erosion payments made to related foreign corporations, and impose a minimum tax if greater than regular tax.

- 20 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(9.)** **INCOME TAXES (Continued)**

The Company does not expect to be materially impacted by the BEAT or FDII provisions and has not included any impact of the provisions in its estimated effective tax rate for 2018, however, it is still in the process of analyzing the effect of these provisions of the Tax Reform Act.

The Company’s worldwide effective tax rate for the third quarter of 2018 was 42.6% on $14.5 million of losses from continuing operations before taxes compared to (2.3)% on $19.4 million of income from continuing operations before taxes for the same period in 2017. The difference between the Company’s effective tax rate and the U.S. federal statutory income tax rate for the third quarter of 2018 is primarily attributable to discrete tax benefits of $3.0 million, which are predominately related to return to provision adjustments and deductible stock based compensation expense. The Company recognized a tax provision of $8.0 million on income from continuing operations before taxes of $35.8 million for the first nine months of 2018 compared to $0.6 million on $33.0 million of income from continuing operations before taxes for the same period of 2017. The 2018 estimated annual effective tax rate includes the estimated impact of all Tax Reform Act provisions.

The Company’s effective tax rate for 2018 differs from the U.S. federal statutory tax rate of 21% due principally to the estimated impact of the GILTI tax. The Company’s earnings outside the United States are generally taxed at blended rates that are marginally lower than the U.S. federal rate. The GILTI provisions require the Company to include foreign subsidiary earnings in excess of a deemed return on the foreign subsidiary’s tangible assets in its U.S. income tax return. There is a statutory deduction of 50% of the GILTI inclusion, however the deduction is subject to limitations based on U.S. taxable income. The Company currently has net operating losses to offset forecasted U.S. taxable income and as such, is temporarily subject to the deduction limitation which correspondingly imposes an incremental impact on U.S. income tax. The foreign jurisdictions in which the Company operates and where its foreign earnings are primarily derived, include Switzerland, Mexico, Uruguay, Malaysia and Ireland.

The Company’s effective tax rate for 2017 differs from the U.S. federal statutory tax rate of 35% due principally to the Company’s earnings outside the U.S. which are generally taxed at rates lower than the U.S. federal rate. In addition, the Company had positive income before taxes in its foreign jurisdictions but losses before taxes in U.S. jurisdictions.

As of September 28, 2018, the balance of unrecognized tax benefits from continuing operations is approximately $5.2 million. It is reasonably possible that a reduction of up to $1.1 million of the balance of unrecognized tax benefits may occur within the next twelve months as a result of potential audit settlements. Approximately $5.2 million of the balance of unrecognized tax benefits would favorably impact the effective tax rate, net of federal benefit on state issues, if recognized.

**(10.) COMMITMENTS AND CONTINGENCIES**

**Litigation**

The Company is subject to litigation arising from time to time in the ordinary course of its business. The Company does not expect that the ultimate resolution of any pending legal actions will have a material effect on its consolidated results of operations, financial position, or cash flows. However, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action, which the Company currently believes to be immaterial, will not become material in the future.

In April 2013, the Company commenced an action against AVX Corporation and AVX Filters Corporation (collectively “AVX”) alleging that AVX had infringed on the Company’s patents by manufacturing and selling filtered feedthrough assemblies used in implantable pacemakers and cardioverter defibrillators that incorporate the Company’s patented technology. On January 26, 2016, a jury in the U.S. District Court for the District of Delaware returned a verdict finding that AVX infringed two Integer patents and awarded Integer $37.5 million in damages. Following a second trial in August 2017, a jury found that AVX infringed an additional Integer patent. On March 30, 2018, the U.S. District Court for the District of Delaware vacated the original damage award and ordered a retrial on damages, which is scheduled for January 2019. The Company has recorded no gains in connection with this litigation as no cash has been received.

- 21 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(10.) COMMITMENTS AND CONTINGENCIES (Continued)**

**Product Warranties**

The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The Company does not expect future product warranty claims will have a material effect on its condensed consolidated results of operations, financial position, or cash flows. However, there can be no assurance that any future customer complaints or negative regulatory actions regarding the Company’s products, which the Company currently believes to be immaterial, does not become material in the future. The change in product warranty liability was comprised of the following (in thousands):

|  |  |  |
| --- | --- | --- |
| December 29, 2017 | $ | 2,820 |
| Additions to warranty reserve |  | 570 |
|  |  |  |
| Warranty claims settled |  | (317) |
| September 28, 2018 | $ | 3,073 |
|  |  |  |

**Foreign Currency Contracts**

The Company periodically enters into foreign currency forward contracts to hedge its exposure to foreign currency exchange rate fluctuations in its international operations. The Company has designated these foreign currency forward contracts as cash flow hedges. Accordingly, the effective portions of the unrealized gains and losses on these contracts are reported in Accumulated Other Comprehensive Income in the Condensed Consolidated Balance Sheets and are reclassified to earnings in the same periods during which the hedged transactions affect earnings. The estimated Accumulated Other Comprehensive Income related to the Company’s foreign currency contracts that is expected to be reclassified into earnings within the next twelve months is a $0.7 million gain.

The impact to the Company’s results of operations from its forward contract hedges is as follows (in thousands):

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended** | | | | |  | **Nine Months Ended** | | | |
|  |  |  | |  |  |  |  |  | |  |  |
|  |  | **September 28,** | |  | **September 29,** | |  | **September 28,** | |  | **September 29,** |
|  |  | **2018** |  |  | **2017** |  |  | **2018** |  |  | **2017** |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Increase (decrease) in sales | $ | (252) |  | $ | 594 |  | $ | (254) |  | $ | 733 |
| Increase (decrease) in cost of sales |  | (393) |  |  | (512) |  |  | (988) |  |  | 371 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Ineffective portion of change in fair value |  | — | |  | — | |  | — | |  | — |
|  |  |  |  |  |  |  |  |  |  |  |  |

Information regarding outstanding foreign currency contracts designated as cash flow hedges as of September 28, 2018 is as follows (dollars in thousands):

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Aggregate** | |  |  |  |  |  |  |  |  |  |  |  |
|  | **Notional** | | **Start** | | **End** | |  |  |  |  | **Fair** | |  |
|  | **Amount** | | **Date** | | **Date** | | **$/Foreign Currency** | | |  | **Value** | | **Balance Sheet Location** |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| $ | 1,050 |  | Jul 2018 | | Dec 2018 | | 0.0500 | Peso | | $ | 62 |  | Prepaid expenses and other current assets |
|  | 7,599 |  | Jan 2018 | | Dec 2018 | | 0.0507 | Peso | |  | 340 |  | Prepaid expenses and other current assets |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | 6,100 |  | Jan 2018 | | Dec 2018 | | 1.1961 | Euro | |  | (214) |  | Accrued expenses |
|  | 5,850 |  | Aug 2018 | | Dec 2018 | | 1.1699 | Euro | |  | (16) |  | Accrued expenses |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | 12,621 |  | Jan 2019 | | Jun 2019 | | 1.1686 | Euro | |  | 129 |  | Prepaid expenses and other current assets |
|  | 10,991 |  | Jan 2019 | | Jun 2019 | | 0.0523 | Peso | |  | (95) |  | Accrued expenses |
|  |  |  |  |  |  |  |  | - 22 - |  |  |  |  |  |

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(11.)** **EARNINGS (LOSS) PER SHARE (“EPS”)**

The following table sets forth a reconciliation of the information used in computing basic and diluted EPS (in thousands, except per share amounts):

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended** | | | | |  | **Nine Months Ended** | | | |
|  |  |  | |  |  |  |  |  | |  |  |
|  |  | **September 28,** | |  | **September 29,** | |  | **September 28,** | |  | **September 29,** |
|  |  | **2018** |  |  | **2017** |  |  | **2018** |  |  | **2017** |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Numerator for basic and diluted EPS: |  |  |  |  |  |  |  |  |  |  |  |
| Income (loss) from continuing operations | $ | (8,303) |  | $ | 19,882 |  | $ | 27,837 |  | $ | 32,389 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Income (loss) from discontinued operations |  | 122,382 |  | $ | (6,192) |  |  | 114,382 |  |  | (20,048) |
| Net income | $ | 114,079 |  | $ | 13,690 |  | $ | 142,219 |  | $ | 12,341 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Denominator for basic and diluted EPS: |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Weighted average shares outstanding - Basic |  | 32,211 |  |  | 31,594 |  |  | 32,050 |  |  | 31,304 |
| Dilutive effect of assumed exercise of stock options, restricted stock |  |  |  |  |  |  |  |  |  |  |  |
| and RSUs |  | — | |  | 579 |  |  | 401 |  |  | 643 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Weighted average shares outstanding - Diluted |  | 32,211 |  |  | 32,173 |  |  | 32,451 |  |  | 31,947 |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Basic earnings (loss) per share: |  |  |  |  |  |  |  |  |  |  |  |
| Income (loss) from continuing operations | $ | (0.26) |  | $ | 0.63 |  | $ | 0.87 |  | $ | 1.03 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Income (loss) from discontinued operations |  | 3.80 |  |  | (0.20) |  |  | 3.57 |  |  | (0.64) |
| Basic earnings per share |  | 3.54 |  |  | 0.43 |  |  | 4.44 |  |  | 0.39 |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Diluted earnings (loss) per share: |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Income (loss) from continuing operations | $ | (0.26) |  | $ | 0.62 |  | $ | 0.86 |  | $ | 1.01 |
| Income (loss) from discontinued operations |  | 3.80 |  |  | (0.19) |  |  | 3.52 |  |  | (0.63) |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Diluted earnings per share |  | 3.54 |  |  | 0.43 |  |  | 4.38 |  |  | 0.39 |
|  |  |  |  |  |  |  |  |  |  |  |  |

The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands):

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Three Months Ended** | | | | **Nine Months Ended** | | |
|  |  | |  |  |  | |  |
|  | **September 28,** | | **September 29,** | | **September 28,** | | **September 29,** |
|  | **2018** |  | **2017** |  | **2018** |  | **2017** |
|  |  |  |  |  |  |  |  |
| Time-vested stock options, restricted stock and RSUs | 797 |  | 295 |  | 436 |  | 850 |
| Performance-vested restricted stock and PSUs | 303 |  | 188 |  | 220 |  | 320 |
|  | - 23 - |  |  |  |  |  |  |

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **(12.) ACCUMULATED OTHER COMPREHENSIVE INCOME** | | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Accumulated Other Comprehensive Income is comprised of the following (in thousands): | | | | | | | |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Defined** | |  |  |  |  | **Foreign** | |  |  |  |  |  |  |  |  |  |
|  |  | **Benefit** | |  | **Cash** | |  | **Currency** | |  | **Total** | |  |  |  |  |  |  |
|  |  | **Plan** | |  | **Flow** | |  | **Translation** | |  | **Pre-Tax** | |  |  |  |  | **Net-of-Tax** |  |
|  |  | **Liability** | |  | **Hedges** | |  | **Adjustment** | |  | **Amount** | |  | **Tax** | |  | **Amount** |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **June 29, 2018** | $ | (1,422) |  | $ | 5,094 |  | $ | 37,756 |  | $ | 41,428 |  | $ | (370) |  | $ | 41,058 |  |
| Unrealized gain on cash flow hedges |  | — | |  | 1,424 |  |  | — | |  | 1,424 |  |  | (299) |  |  | 1,125 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Realized gain on foreign currency hedges |  | — | |  | (141) |  |  | — | |  | (141) |  |  | 30 |  |  | (111) |  |
| Realized gain on interest rate swap hedges |  | — | |  | (482) |  |  | — | |  | (482) |  |  | 102 |  |  | (380) |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Foreign currency translation loss |  | — | |  | — | |  | (2,809) |  |  | (2,809) |  |  | — | |  | (2,809) |  |
| Reclassifications to earnings(1) |  | 948 |  |  | — | |  | (514) |  |  | 434 |  |  | (282) |  |  | 152 |  |
| **September 28, 2018** | $ | (474) |  | $ | 5,895 |  | $ | 34,433 |  | $ | 39,854 |  | $ | (819) |  | $ | 39,035 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **December 29, 2017** | $ | (1,422) |  | $ | 3,418 |  | $ | 50,200 |  | $ | 52,196 |  | $ | (17) |  | $ | 52,179 |  |
| Unrealized gain on cash flow hedges |  | — | |  | 4,325 |  |  | — | |  | 4,325 |  |  | (908) |  |  | 3,417 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Realized gain on foreign currency hedges |  | — | |  | (734) |  |  | — | |  | (734) |  |  | 154 |  |  | (580) |  |
| Realized gain on interest rate swap hedges |  | — | |  | (1,114) |  |  | — | |  | (1,114) |  |  | 234 |  |  | (880) |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Foreign currency translation loss |  | — | |  | — | |  | (15,253) |  |  | (15,253) |  |  | — | |  | (15,253) |  |
| Reclassifications to earnings(1) |  | 948 |  |  | — | |  | (514) |  |  | 434 |  |  | (282) |  |  | 152 |  |
| **September 28, 2018** | $ | (474) |  | $ | 5,895 |  | $ | 34,433 |  | $ | 39,854 |  | $ | (819) |  | $ | 39,035 |  |
| **June 30, 2017** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| $ | (1,475) |  | $ | 4,601 |  | $ | 25,475 |  | $ | 28,601 |  | $ | (1,398) |  | $ | 27,203 |  |
|  |  |  | |  |  |  |  |  | |  |  |  |  |  |  |  |  |  |
| Unrealized gain on cash flow hedges |  | — | |  | 633 |  |  | — | |  | 633 |  |  | (222) |  |  | 411 |  |
| Realized gain on foreign currency hedges |  | — | |  | (1,106) |  |  | — | |  | (1,106) |  |  | 387 |  |  | (719) |  |
|  |  |  | |  |  |  |  |  | |  |  |  |  |  |  |  |  |  |
| Realized gain on interest rate swap hedges |  | — | |  | (49) |  |  | — | |  | (49) |  |  | 18 |  |  | (31) |  |
| Foreign currency translation gain |  | — | |  | — | |  | 16,728 |  |  | 16,728 |  |  | — | |  | 16,728 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **September 29, 2017** | $ | (1,475) |  | $ | 4,079 |  | $ | 42,203 |  | $ | 44,807 |  | $ | (1,215) |  | $ | 43,592 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **December 30, 2016** | $ | (1,475) |  | $ | 1,420 |  | $ | (15,660) |  | $ | (15,715) |  | $ | (285) |  | $ | (16,000) |  |
| Unrealized gain on cash flow hedges |  | — | |  | 3,414 |  |  | — | |  | 3,414 |  |  | (1,195) |  |  | 2,219 |  |
|  |  |  | |  |  |  |  |  | |  |  |  |  |  |  |  |  |  |
| Realized gain on foreign currency hedges |  | — | |  | (362) |  |  | — | |  | (362) |  |  | 127 |  |  | (235) |  |
| Realized gain on interest rate swap hedges |  | — | |  | (393) |  |  | — | |  | (393) |  |  | 138 |  |  | (255) |  |
|  |  |  | |  |  | |  |  |  |  |  |  |  |  | |  |  |  |
| Foreign currency translation gain |  | — | |  | — | |  | 57,863 |  |  | 57,863 |  |  | — | |  | 57,863 |  |
| **September 29, 2017** | $ | (1,475) |  | $ | 4,079 |  | $ | 42,203 |  | $ | 44,807 |  | $ | (1,215) |  | $ | 43,592 |  |
| \_\_\_\_\_\_\_\_\_\_ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

1. Accumulated foreign currency translation losses of $0.5 million and defined benefit plan liabilities of $0.7 million (net of income taxes of $0.3 million) were reclassified to earnings in during the three months ended September 28, 2018 as a result of the divestiture of the AS&O Product Line and are included in “Gain on sale of discontinued operations, net of tax” in the Condensed Consolidated Statements of Operations.

The realized loss (gain) relating to the Company’s foreign currency hedges were reclassified from Accumulated Other Comprehensive Income and included in Cost of Sales or Sales as the transactions they are hedging occur. The realized gain relating to the Company’s interest rate swap hedges were reclassified from Accumulated Other Comprehensive Income and included in Interest Expense as interest on the corresponding debt being hedged is accrued.

- 24 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(13.)** **FAIR VALUE MEASUREMENTS**

**Assets and Liabilities Measured at Fair Value on a Recurring Basis**

Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis. The Company also holds cost method and equity method investments which are measured at fair value on a nonrecurring basis.

***Foreign Currency Contracts***

The fair value of foreign currency contracts were determined through the use of cash flow models that utilize observable market data inputs to estimate fair value. These observable market data inputs included foreign exchange rate and credit spread curves. In addition, the Company received fair value estimates from the foreign currency contract counterparties to verify the reasonableness of the Company’s estimates. The Company’s foreign currency contracts are categorized in Level 2 of the fair value hierarchy. Refer to Note 10 “Commitments and Contingencies” for further discussion regarding the fair value of the Company’s foreign currency contracts.

***Interest Rate Swaps***

The fair value of the Company’s interest rate swap contract outstanding were determined through the use of a cash flow model that utilizes observable market data inputs. These observable market data inputs include LIBOR, swap rates, and credit spread curves. In addition, the Company received a fair value estimate from the interest rate swap counterparty to verify the reasonableness of the Company’s estimate. Refer to Note 5 “Debt” for further discussion regarding the fair value of the Company’s interest rate swap.

The following table provides information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands):

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  | **Quoted** |  |  |  | **Significant** | |  |  |
|  |  |  |  | **Prices in** |  |  |  | **Other** | |  | **Significant** |
|  |  |  |  | **Active** |  |  |  | **Observable** | |  | **Unobservable** |
|  |  |  |  | **Markets** |  |  |  | **Inputs** | |  | **Inputs** |
|  |  | **Fair Value** | | **(Level 1)** |  |  |  | **(Level 2)** | |  | **(Level 3)** |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **September 28, 2018** |  |  |  |  |  |  |  |  |  |  |  |
| Assets: Interest rate swap (Note 5) | $ | 5,690 |  | $ | — | | $ | 5,690 |  | $ | — |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Assets: Foreign currency contracts (Note 10) |  | 531 |  |  | — | |  | 531 |  |  | — |
| Liabilities: Foreign currency contracts (Note 10) |  | 325 |  |  | — | |  | 325 |  |  | — |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **December 29, 2017** |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Assets: Interest rate swaps | $ | 4,279 |  | $ | — | | $ | 4,279 |  | $ | — |
| Liabilities: Foreign currency contracts |  | 861 |  |  | — | |  | 861 |  |  | — |

**Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis**

Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. The carrying amounts of cash, accounts receivable, accounts payable, and accrued expenses approximate fair value because of the short-term nature of these items. Refer to Note 5 “Debt” for further discussion regarding the fair value of the Company’s Senior Secured Credit Facilities and Senior Notes. A summary of the valuation methodologies for assets and liabilities measured on a nonrecurring basis is as follows:

***Cost and Equity Method Investments***

The Company holds investments in equity and other securities that are accounted for as either cost method or equity method investments, which are classified as Other Assets on the Condensed Consolidated Balance Sheets. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost method investments are not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investments. The aggregate recorded amount of cost and equity method investments at September 28, 2018 and December 29, 2017 was $23.1 million and $20.8 million, respectively.

- 25 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(13.)** **FAIR VALUE MEASUREMENTS (Continued)**

As of September 28, 2018 and December 29, 2017, the recorded amount of the Company’s equity method investment was $15.4 million and $13.8 million, respectively. The Company’s equity method investment is in a Chinese venture capital fund focused on investing in life sciences companies. This fund accounts for its investments at fair value with the unrealized change in fair value of these investments recorded as income or loss to the fund in the period of change. As of September 28, 2018, the Company owned 6.7% of this fund. During the nine months ended September 28, 2018 and September 29, 2017, the Company recognized net gains of $5.5 million and $2.3 million, respectively, on its equity method investment.

The Company’s recorded amount of cost method investments was $7.7 million and $7.0 million at September 28, 2018 and December 29, 2017, respectively. The Company did not recognize any impairment charges related to cost method investments during the nine months ended September 28, 2018. The Company recognized impairment charges of $5.3 million related to its cost method investments during the nine months September 29, 2017. The fair value of these investments is primarily determined by reference to recent sales data of similar shares to independent parties in an inactive market and categorized in Level 2 of the fair value hierarchy.

**(14.) SEGMENT INFORMATION**

The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. This segment structure reflects the financial information and reports used by the Company’s management, specifically its Chief Operating Decision Maker (“CODM”), to make decisions regarding the Company’s business, including resource allocations and performance assessments. This segment structure reflects the Company’s current operating focus in compliance with ASC 280, *Segment Reporting*. There were no sales between segments during the nine months ended September 28, 2018 and September 29, 2017.

The following table presents sales from continuing operations by product line (in thousands).

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended** | | | | |  | **Nine Months Ended** | | | |
|  |  |  | |  |  |  |  |  | |  |  |
|  |  | **September 28,** | |  | **September 29,** | |  | **September 28,** | |  | **September 29,** |
|  |  | **2018** |  |  | **2017** |  |  | **2018** |  |  | **2017** |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Segment sales from continuing operations by product line:** |  |  |  |  |  |  |  |  |  |  |  |
| Medical |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Cardio & Vascular | $ | 150,230 |  | $ | 137,712 |  | $ | 435,859 |  | $ | 391,914 |
| Cardiac & Neuromodulation |  | 109,620 |  |  | 101,612 |  |  | 334,471 |  |  | 311,540 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Advanced Surgical, Orthopedics & Portable Medical |  | 32,789 |  |  | 31,715 |  |  | 101,481 |  |  | 88,148 |
| Total Medical |  | 292,639 |  |  | 271,039 |  |  | 871,811 |  |  | 791,602 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Non-Medical |  | 12,449 |  |  | 15,129 |  |  | 40,167 |  |  | 42,218 |
| Total sales from continuing operations | $ | 305,088 |  | $ | 286,168 |  | $ | 911,978 |  | $ | 833,820 |
|  |  |  |  |  |  |  |  |  |  |  |  |

The following table presents income from continuing operations for the Company’s reportable segments (in thousands).

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended** | | | | |  | **Nine Months Ended** | | | |
|  |  |  | |  |  |  |  |  | |  |  |
|  |  | **September 28,** | |  | **September 29,** | |  | **September 28,** | |  | **September 29,** |
|  |  | **2018** |  |  | **2017** |  |  | **2018** |  |  | **2017** |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Segment income from continuing operations:** |  |  |  |  |  |  |  |  |  |  |  |
| Medical | $ | 58,929 |  | $ | 47,363 |  | $ | 167,623 |  | $ | 146,637 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Non-Medical |  | 3,521 |  |  | 3,375 |  |  | 11,112 |  |  | 9,877 |
| Total segment income from continuing operations |  | 62,450 |  |  | 50,738 |  |  | 178,735 |  |  | 156,514 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Unallocated operating expenses |  | (20,991) |  |  | (14,912) |  |  | (62,875) |  |  | (60,723) |
| Operating income from continuing operations |  | 41,459 |  |  | 35,826 |  |  | 115,860 |  |  | 95,791 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Unallocated expenses, net |  | (55,919) |  |  | (16,392) |  |  | (80,067) |  |  | (62,806) |
| Income before taxes from continuing operations | $ | (14,460) |  | $ | 19,434 |  | $ | 35,793 |  | $ | 32,985 |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | - 26 - |  |  |  |  |  |  |  |  |  |

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(15.)** **REVENUE FROM CONTRACTS WITH CUSTOMERS**

The majority of the Company’s revenues consist of sales of various medical devices and products to large, multinational OEMs and their affiliated subsidiaries. The Company considers the customer’s purchase order, which in some cases is governed by a long-term agreement, and the Company’s corresponding sales order acknowledgment as the contract with the customer. The Company has elected to adopt the practical expedient provided in ASC 340-40-25-4 and recognize the incremental costs of obtaining a contract, which are primarily sales commissions, as expense when incurred because the amortization period is less than one year.

**Performance Obligations**

The Company considers each shipment of an individual product included on a purchase order to be a separate performance obligation, as each shipment is separately identifiable and the customer can benefit from each individual product separately from the other products included on the purchase order. Accordingly, a contract can have one or more performance obligations to manufacture products. Standard payment terms range from 30 to 90 days and can include a discount for early payment.

The Company does not offer its customers a right of return. Rather, the Company warrants that each unit received by the customer will meet the agreed upon technical and quality specifications and requirements. Only when the delivered units do not meet these requirements can the customer return the non-compliant units as a corrective action under the warranty. The remedy offered to the customer is repair of the returned units or replacement if repair is not viable. Accordingly, the Company records a warranty reserve and any warranty activities are not considered to be a separate performance obligation. Historically, warranty reserves have not been material.

**Transaction Price**

Generally, the transaction price of the Company’s contracts consists of a unit price for each individual product included in the contract, which can be fixed or variable based on the number of units ordered. In some instances, the transaction price also includes a rebate for meeting certain volume-based targets over a specified period of time. The transaction price of a contract is determined based on the unit price and the number of units ordered, reduced by the rebate expected to be earned on those units. Rebates are estimated based on the expected achievement of the volume-based target using the most likely amount method and updated quarterly. Any adjustments to these estimates are recognized under the cumulative catch-up method, such that impact of the adjustment is recognized in the period in which it is identified.

The transaction price is allocated to each performance obligation on a relative standalone selling price basis. As the majority of products sold to customers are manufactured to meet the specific requirements and technical specifications of that customer, the products are considered unique to that customer and the unit price stated in the contract is considered the standalone selling price.

The Company has elected to adopt the practical expedient provided in ASC 606-10-50-14 and not disclose the aggregate amount of the transaction price allocated to unsatisfied performance obligations and an expectation of when those amounts are expected to be recognized as revenue because the majority of contracts have an original expected duration of one year or less.

**Revenue Recognition**

The Company recognizes revenue at the point in time when a performance obligation is satisfied and the customer has obtained control of the products. Control is defined as the ability to direct the use of and obtain substantially all of the remaining benefits of the product. The customer obtains control of the products when title and risk of ownership transfers to them, which is primarily based upon shipping terms. Accordingly, the majority of the Company’s revenues are recognized at the point of shipment. In instances where title and risk of ownership do not transfer to the customer until the products have reached the customer’s location, revenue is recognized at that point in time. Revenue is recognized net of sales tax, value-added taxes and other taxes.

**Contract Modifications**

Contract modifications, which can include a change in either or both scope and price, most often occur related to contracts that are governed by a long-term arrangement. Contract modifications typically relate to the same products already governed by the long-term arrangement, and therefore, are accounted for as part of the existing contract. If a contract modification is for additional products, it is accounted for as a separate contract.

- 27 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(15.)** **REVENUE FROM CONTRACTS WITH CUSTOMERS (Continued)**

**Disaggregated Revenue**

In general, the Company's business segmentation is aligned according to the nature and economic characteristics of its products and customer relationships and provides meaningful disaggregation of each business segment's results of operations. For a summary by disaggregated product line sales for each segment, refer to Note 14, “Segment Information.” Additionally, the tables below disaggregate the Company’s revenues based upon significant customers, which are defined as any customer who individually represents 10% or more of a segment’s total revenues, and ship to country, which is defined as any country where 10% or more of a segment’s total revenues are shipped to. The Company believes that these categories best depict how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| The following table presents revenues by customer. | |  |  |  |  |  |  |  |
|  |  | **Three Months Ended** | | | | **Nine Months Ended** | | |
|  |  | **September 28, 2018** | | | | **September 28, 2018** | | |
|  | |  | |  |  |  | |  |
| **Customer** | | **Medical** | | **Non-Medical** | | **Medical** | | **Non-Medical** |
|  |  |  |  |  |  |  |  |  |
| Customer A | | 23% |  | —% | | 22% |  | —% |
| Customer B | | 20% |  | —% | | 19% |  | —% |
|  |  |  |  |  |  |  |  |  |
| Customer C | | 12% |  | —% | | 12% |  | —% |
| Customer D | | —% | | 30% |  | —% | | 28% |
|  |  |  |  |  |  |  |  |  |
| All other customers | | 45% |  | 70% |  | 47% |  | 72% |
|  |  |  |  |  |  |  |  |  |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| The following table presents revenues by ship to country. | |  |  |  |  |  |  |  |
|  |  | **Three Months Ended** | | | | **Nine Months Ended** | | |
|  |  | **September 28, 2018** | | | | **September 28, 2018** | | |
|  | |  | |  |  |  | |  |
| **Ship to Location** | | **Medical** | | **Non-Medical** | | **Medical** | | **Non-Medical** |
|  |  |  |  |  |  |  |  |  |
| United States | | 58% |  | 65% |  | 56% |  | 68% |
| Puerto Rico | | 13% |  | —% | | 13% |  | —% |
|  |  |  |  |  |  |  |  |  |
| Canada | | —% | | 10% |  | —% | | 10% |
| All other Countries | | 29% |  | 25% |  | 31% |  | 22% |

**Contract Balances**

The timing of revenue recognition, billings and cash collections results in billed accounts receivable and less frequently, unearned revenue. Accounts receivable are recorded when the right to consideration becomes unconditional. Unearned revenue is recorded when customers pay or are billed in advance of the Company’s satisfaction of performance obligations. Contract liabilities were $4.1 million and $2.2 million as of September 28, 2018 and December 29, 2017, respectively, and are classified as Accrued Expenses on the Condensed Consolidated Balance Sheets. During the three and nine months ended September 28, 2018, the Company recognized $0.2 million and $0.6 million, respectively, of revenue that was included in the contract liability balance as of December 29, 2017. The Company does not have any contract assets.

- 28 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(16.)** **IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS**

The following table provides a brief description of recent Accounting Standard Updates ("ASU") issued by the Financial Accounting Standards Board ("FASB"):

**Effect on the Financial Statements or**

**Standard** **Description** **Effective Date** **Other Significant Matters**




In August 2018, the FASB issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract

In August 2018, the FASB issued ASU 2018-13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value

In July 2018, the FASB issued ASU 2018-11, Leases Targeted Improvements

The new guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop internal-use software, such that costs for implementation activities in the application development stage are capitalized and amortized over the life of term of the hosting arrangement, while costs incurred during the preliminary project and post implementation stages are expensed as performed.



The new guidance removes certain disclosure requirements from Topic 820, including the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels and the valuation processes for Level 3 fair value measurements. This ASU also clarifies that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date and now requires disclosure of the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average (or other quantitative information if more reasonable) of significant unobservable inputs used to develop Level 3 fair value measurements.

The new guidance provides entities with an additional (and optional) transition method to adopt the new standard by initially applying the standard at the adoption date (vs. the earliest period presented) and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Additionally, lessors are provided with a practical expedient to not separate non-lease components from the associated lease component and accounts for those components as a single component if certain criteria are met.

January 4, 2020 (beginning of 2020 fiscal year). Early adoption is permitted.

January 4, 2020 (beginning of 2020 fiscal year). Early adoption is permitted.

December 29, 2018 (beginning of 2019 fiscal year). Early adoption is permitted.

The Company is currently evaluating the impact that the adoption of this ASU will have on its consolidated financial statements.

The Company is currently evaluating the impact that the adoption of this ASU will have on its consolidated financial statements.

The Company plans to adopt ASC Topic 842 using the transition method offered through this ASU; refer to the discussion of ASC 2016-02 below for further detail.


- 29 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **(16.) IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS (Continued)** | | | | | |  |
|  |  |  |  |  |  | **Effect on the Financial Statements or** |
| **Standard** | | **Description** | | **Effective Date** | | **Other Significant Matters** |
|  |  |  |  |  |  |  |
| In July 2018, the FASB | | The new guidance amends and clarifies the following | | December 29, 2018 | | These amendments will be considered and |
| issued ASU 2018-10, | | areas of Topic 842: residual value guarantees, rate | | (beginning of 2019 | | incorporated into the Company’s |
| Codification Improvements | | implicit in the lease, lessee reassessment of lease | | fiscal year). Early | | implementation of ASC Topic 842; refer to |
| to Topic 842 Leases | | classification, lessor reassessment of lease term and | | adoption is permitted. | | the discussion of ASC 2016-02 below for |
|  |  | purchase option, variable lease payments that depend | |  |  | further detail. |



on an index or rate, investment tax credits, lease term

and purchase option, transition guidance for amounts

previously recognized in business combinations,

certain transition adjustments, transition guidance for

leases previously classified as capital leases under

Topic 840, transition guidance for modifications to

leases previously classified as direct financing or

sales-type leases under Topic 840, transition guidance

for sale and leaseback transaction, impairment of net

investment in the lease, unguaranteed residual asset,

effect of initial direct costs on rate implicit in the lease

and failed sale and leaseback transactions.

In February 2018, the FASB issued ASU 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.

The new guidance allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act and will improve the usefulness of information reported to financial statement users.

December 29, 2018 (beginning of 2019 fiscal year). Early adoption is permitted.

The Company is currently evaluating the impact that the adoption of this ASU will have on its consolidated financial statements.

|  |  |  |  |
| --- | --- | --- | --- |
| In August 2017, the FASB | The new guidance improves the financial reporting of | December 29, 2018 | The Company does not believe the |
| issued ASU 2017-12, | hedging relationships to better portray the economic | (beginning of 2019 | adoption of this guidance will have a |
| Targeted Improvements to | results of an entity's risk management activities in its | fiscal year). Early | material impact on its consolidated |
| Accounting for Hedging | financial statements through changes to both the | adoption is permitted. | financial statements. |
| Activities. | designation and measurement guidance for qualifying |  |  |
|  | hedging relationships and the presentation of hedge |  |  |
|  | results. |  |  |
|  |  |  |  |

In March 2017, the FASB issued ASU 2017-07, Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.

The new guidance clarifies the presentation and classification of the components of net periodic benefit costs in the consolidated statement of operations.

December 30, 2017 (beginning of 2018 fiscal year).

The Company adopted the new guidance effective December 30, 2017, the beginning of its 2018 fiscal year, using the retrospective transition method, as part of the FASB's simplification initiative. See *Adoption of ASU 2017-07* section belowfor additional information.

|  |  |  |  |
| --- | --- | --- | --- |
| In October 2016, the FASB | The new guidance requires the income tax | December 30, 2017 | The Company adopted the new guidance |
| issued ASU 2016-16, Intra- | consequences of an intra-entity transfer of assets other | (beginning of 2018 | effective December 30, 2017. The adoption |
| Entity Transfers of Assets | than inventory to be recognized when the transfer | fiscal year). | of the new guidance did not have a |
| Other Than Inventory. | occurs rather than deferring until an outside sale has |  | material impact to the Company. |
|  | occurred. |  |  |
|  |  |  |  |

- 30 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(16.)** **IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS (Continued)**

**Effect on the Financial Statements or**

**Standard** **Description** **Effective Date** **Other Significant Matters**



In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments.

The new guidance clarifies the presentation and classification of certain cash receipts and cash payments in the statement of cash flows.


December 30, 2017 (beginning of 2018 fiscal year).

The Company adopted the new guidance effective December 30, 2017. The adoption of the new guidance did not have a material impact to the Company.

|  |  |  |  |
| --- | --- | --- | --- |
| In February 2016, the | The new guidance supersedes the lease guidance | December 29, 2018 | The Company is currently evaluating its |
| FASB issued ASU 2016- | under ASC Topic 840, *Leases*, resulting in the | (beginning of 2019 | population of leases, and is continuing to |
| 02, Leases. | creation of FASB ASC Topic 842, *Leases*. The | fiscal year). Early | assess all potential impacts of the standard, |
|  | guidance requires a lessee to recognize in the | adoption is permitted. | but currently believes the most significant |
|  | statement of financial position a liability to make lease |  | impact relates to its accounting for real |
|  | payments and a right-of-use asset representing its right |  | estate operating leases. The Company |
|  | to use the underlying asset for the lease term for both |  | anticipates recognition of right of use |
|  | finance and operating leases. |  | assets and corresponding lease liabilities |
|  |  |  | related to leases upon adoption, but has not |
|  |  |  | yet quantified these at this time. The |
|  |  |  | Company plans to elect the package of |
|  |  |  | three practical expedients and adopt the |
|  |  |  | standard effective December 29, 2018, |
|  |  |  | using the transition method made available |
|  |  |  | in ASU 2018-11. |
|  |  |  |  |

In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities.

The new guidance updates certain aspects of recognition, measurement, presentation and disclosure of financial instruments.



December 30, 2017 (beginning of 2018 fiscal year).

The Company adopted the new guidance effective December 30, 2017. The adoption of the new guidance did not have a material impact to the Company.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. Since that date, the FASB has issued additional ASUs clarifying certain aspects of ASU 2014-09.

The new guidance requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The new guidance provides alternative methods of adoption. Subsequent guidance issued after May 2014 did not change the core principle of ASU 2014-09.

December 30, 2017 (beginning of 2018 fiscal year).

The Company adopted the new guidance effective December 30, 2017, using the modified retrospective transition method applied to those contracts which were not completed as of December 30, 2017. Prior period amounts have not been adjusted and continue to be reflected in accordance with the Company’s historical accounting. The adoption of this ASU did not have a material impact on the consolidated financial statements and therefore no cumulative adjustment was recorded to equity. The Company has updated its internal controls for changes and expanded disclosures have been made in the Notes to the Financial Statements as a result of adopting the standard. (See Note 15, “Revenue from Contracts with Customers”).

- 31 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(16.)** **IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS (Continued)**

**Adoption of ASU 2017-07**

On December 30, 2017, the Company retrospectively adopted the new accounting guidance on presentation of net periodic pension costs (ASU 2017-07). That guidance requires that the service cost component of net benefit costs be disaggregated and reported in the same line item or items in the Condensed Consolidated Statements of Operations as other compensation costs arising from services rendered by the pertinent employees during the period. The other non-service components of net benefit costs are required to be presented separately from the service cost component.

Following the adoption of this guidance, the Company continues to record the service cost component of net benefit costs in Cost of Sales and Selling, General and Administrative expenses. The interest cost component of net benefit costs is now recorded in Interest Expense and the remaining components of net benefit costs, amortization of net losses and expected return on plan assets, are now recorded in Other (Income) Loss, Net.

- 32 -

**ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*This Quarterly Report on Form 10-Q should be read in conjunction with the disclosures included in our Annual Report on Form 10-K for the fiscal year ended December 29, 2017. In addition, please read this section in conjunction with our Condensed Consolidated Financial Statements and Notes to Condensed Consolidated Financial Statements contained herein.*

**Forward-Looking Statements**

Some of the statements contained in this report and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include statements relating to:

* future sales, expenses, and profitability;
* future development and expected growth of our business and industry;
* our ability to execute our business model and our business strategy;
* our ability to identify trends within our industries and to offer products and services that meet the changing needs of those markets;
* our ability to remain in compliance with the financial covenants contained in the agreement governing our Senior Secured Credit Facilities; and
* projected capital expenditures.

You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or “variations” or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this report.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the following: our high level of indebtedness, our inability to pay principal and interest on this high level of outstanding indebtedness or to remain in compliance with financial and other covenants under our Senior Secured Credit Facilities, and the risk that this high level of indebtedness limits our ability to invest in our business and overall financial flexibility; our dependence upon a limited number of customers; customer ordering patterns; product obsolescence; our inability to market current or future products; pricing pressure from customers; our ability to timely and successfully implement cost savings and consolidation initiatives; our reliance on third party suppliers for raw materials, products and subcomponents; fluctuating operating results; our inability to maintain high quality standards for our products; challenges to our intellectual property rights; product liability claims; product field actions or recalls; our inability to successfully consummate and integrate acquisitions and to realize synergies and to operate these acquired businesses in accordance with expectations; our unsuccessful expansion into new markets; our failure to develop new products; the timing, progress and ultimate success of pending regulatory actions and approvals; our inability to obtain licenses to key technology; regulatory changes, including health care reform, or consolidation in the healthcare industry; global economic factors, including currency exchange rates and interest rates; the resolution of various legal actions brought against the Company; enactment related and ongoing impacts related to the U.S. Tax Cuts and Jobs Act (the “Tax Reform Act”), including the Global Intangible Low-Taxed Income (“GILTI”) tax; and other risks and uncertainties that arise from time to time and are described in Item 1A “Risk Factors” of our Annual Report on Form 10-K and in other periodic filings with the Securities and Exchange Commission. Except as required by applicable law, the Company assumes no obligation to update forward-looking statements in this report whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

- 33 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**MANAGEMENT'S DISCUSSION AND ANALYSIS**

**Our Business**

Integer Holdings Corporation is one of the largest medical device outsource (“MDO”) manufacturers in the world serving the cardiac, neuromodulation, vascular and portable medical markets. We also develop batteries for high-end niche applications in the non-medical energy, military, and environmental markets. Our vision is to enhance the lives of patients worldwide by being our customers’ partner of choice for innovative technologies and services.

We organize our business into two reportable segments, Medical and Non-Medical, and derive our revenues from four principle product lines. The Medical segment includes the Advanced Surgical, Orthopedics & Portable Medical, Cardio & Vascular and Cardiac & Neuromodulation product lines and the Non-Medical segment is comprised of the Electrochem product line.

**Discontinued Operations and Divestiture**

On May 3, 2018, the Company entered into a definitive agreement to sell the Advanced Surgical and Orthopedic product lines (the “AS&O Product Line”) within its Medical segment to Viant (formerly MedPlast, LLC). On July 2, 2018, we completed the sale of the AS&O Product Line for net cash proceeds of approximately $582 million, resulting in a pre-tax gain of approximately $195 million. As a result, we classified the results of operations of the AS&O Product Line as discontinued operations in the Condensed Consolidated Statements of Operations for all periods presented and classified the related assets and liabilities associated with the discontinued operations as held for sale in the Condensed Consolidated Balance Sheet as of December 29, 2017. All results and information presented exclude the AS&O Product Line unless otherwise noted. Refer to Note 2 “Discontinued Operations and Divestiture” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about the divestiture.

In connection with the sale, the parties executed a transition services agreement whereby we will provide certain corporate services (including accounting, payroll, and information technology services) to Viant for a period of up to one year from the date of the closing to facilitate an orderly transfer of business operations. Viant will pay us for these services, with such payments varying in amount and length of time as specified in the transition services agreement. In addition, the parties executed long-term supply agreements under which the parties have agreed to supply the other with certain products at prices specified in the agreements for a term of three years.

**Strategic Overview**

During 2017, we undertook a thorough strategic review of our customers, competitors and markets. As a result of this review, during the fourth quarter of 2017, we began to take steps to better align our resources in order to invest to grow, protect, preserve and to enhance the profitability of our portfolio of products. These steps include focusing our investment in research and development and manufacturing, improving our business processes and redirecting investments away from projects where the market does not justify the investment. The execution of this strategy will be our primary focus going forward.

We believe Integer is well-positioned within the medical technology and MDO manufacturing market and that there is a robust pipeline of opportunities to pursue. We have expanded our medical device capabilities and are excited about opportunities to partner with customers to drive innovation. We believe we have the scale and global presence, supported by world-class manufacturing and quality capabilities, to capture these opportunities. We are confident in our abilities as one of the largest MDO manufacturers, with a long history of successfully integrating companies, driving down costs and growing revenues over the long-term. Ultimately, our strategic vision is to drive shareholder value by enhancing the lives of patients worldwide by being our customers’ partner of choice for innovative technologies and services.

- 34 -

**Revised 2018 Outlook(a)**

(dollars in millions, except per share amounts)

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **GAAP** | | |  |  | **Non-GAAP(b)** | | |
| **Continuing Operations:** | | **As Reported** | | | **Growth** | | **Adjusted** | | **Growth** |
| Sales |  | $1,197 to $1,212 |  |  | 5% to 7% |  | $1,195 to $1,210 |  | 6% to 7% |
|  |  |  |  |  |  |  |  |  |  |
| Net Income | | $44 to $49 | | | (50)% to (44)% | | $117 to $122 | | 18% to 23% |
| EBITDA | | N/A | | | N/A | | $255 to $265 | | 9% to 13% |
|  |  |  |  |  |  |  |  |  |  |
| Earnings per Diluted Share | | $1.34 to $1.49 | | | (51)% to (46)% | | $3.55 to $3.70 | | 15% to 20% |
|  |  |  |  |  |  |  |  |  |  |

1. Except as described below, further reconciliations by line item to the closest corresponding GAAP financial measure for Adjusted Sales, Adjusted Net Income, Adjusted EBITDA, and Adjusted Earnings per Diluted Share, included in our “Revised 2018 Outlook” above, are not available without unreasonable efforts on a forward-looking basis due to the high variability, complexity and visibility of the charges excluded from these non-GAAP financial measures.
2. Adjusted Net Income and EPS for 2018 is expected to consist of GAAP Net Income and EPS, excluding items such as intangible amortization, IP-related litigation costs, consolidation and realignment costs, asset disposition and write-down charges, and loss on extinguishment of debt totaling approximately $89 million. The after-tax impact of these items is estimated to be approximately $70 million, or approximately $2.13 per diluted share. Additionally, Adjusted Net Income and EPS is expected to exclude the estimated impact relating to our disallowed deduction of the GILTI tax, as mandated by the Tax Reform Act. This disallowed deduction of the GILTI tax (approximately 50% of the total GILTI tax) is due to the Company making use of its U.S. net operating losses (“NOLs”), and will be eliminated once the Company’s U.S. NOLs are fully utilized, which is expected to be in 2019. This adjustment makes our Adjusted Diluted EPS more comparable with other global companies that are not subject to this disallowed GILTI tax deduction and more comparable to the Company’s results following the full utilization of its U.S. NOLs.

Adjusted EBITDA is expected to consist of Adjusted Net Income, excluding items such as depreciation, interest, stock-based compensation and taxes totaling approximately $140 million.

* + 35 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**MANAGEMENT'S DISCUSSION AND ANALYSIS**

**Financial Overview of Continuing Operations**

Loss from continuing operations for the third quarter of 2018 was $8.3 million, or $0.26 per diluted share, compared to income from continuing operations of $19.9 million, or $0.62 per diluted share, for the third quarter of 2017. Income from continuing operations for the first nine months of 2018 was $27.8 million, or $0.86 per diluted share, compared to income from continuing operations of $32.4 million, or $1.01 per diluted share, for the first nine months of 2017. These year over year variances are primarily the result of the following:

* Sales from continuing operations for the third quarter and first nine months of 2018 increased 7% and 9%, respectively, primarily driven by market growth and new business wins. In comparison to the prior year periods, foreign currency exchange rates decreased sales by $0.1 million for the third quarter of 2018 and increased sales from continuing operations by approximately $2.3 million for the first nine months of 2018.
* Gross profit from continuing operations for the third quarter and first nine months of 2018 increased $2.7 million and $13.8 million, respectively, primarily due to the increase in sales from continuing operations discussed above, partially offset by higher incentive compensation based upon current year-to-date results.
* Operating expenses for the third quarter and first nine months of 2018 were lower by $2.9 million and $6.2 million, respectively, compared to the same periods in 2017, due to a decrease in other operating expenses attributable to the completion of spending on integration activities and various efficiencies and synergies gained as a result of our integration and consolidation initiatives partially offset by higher incentive compensation.
* Interest expense for the third quarter and first nine months of 2018 increased by $38.7 million and $36.1 million, respectively, compared to the same periods in 2017, primarily due to extinguishment of debt charges related to the repayment of indebtedness in connection with the divestiture of the AS&O Product Line. Debt extinguishment expenses included in interest expense for the third quarter and first nine months of 2018 were higher by $39.9 million and $38.9 million, respectively, compared to the same periods in 2017.
* Net gains on cost and equity method investments, which are unpredictable in nature, increased income for the third quarter and first nine months of 2018 by $0.3 million and $5.5 million, respectively, compared to income of $1.9 million and losses of $2.9 million during the same periods in 2017.
* Other loss, net for the third quarter and first nine months of 2018 was $1.7 million and $0.3 million, respectively, compared to $2.5 million and $10.7 million during the same periods in 2017, primarily due to the non-recurrence of a non-cash foreign currency charge in the prior year on inter-company loans.
* We recorded an income tax benefit of $6.2 million for the third quarter of 2018, compared to a benefit of $0.4 million for the same period of 2017. The income tax provision for the first nine months of 2018 and 2017 was $8.0 million and $0.6 million, respectively. Refer to Note 9 “Income Taxes” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report and the “Provision for Income Taxes” section of this Item for additional information.
  + 36 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**MANAGEMENT'S DISCUSSION AND ANALYSIS**

***Use of Non-GAAP Financial Information***

We prepare our condensed consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”). Additionally, we report and discuss in our earnings releases and investor presentations adjusted pre-tax income, adjusted income, adjusted earnings per diluted share, earnings before interest, taxes, depreciation, and amortization (“EBITDA”), adjusted EBITDA and organic sales growth rates, all from continuing operations. Adjusted pre-tax income, adjusted income and adjusted earnings per diluted share from continuing operations consist of GAAP amounts adjusted for the following to the extent occurring during the period: (i) acquisition and integration related charges and expenses, (ii) amortization of intangible assets including inventory step-up amortization, (iii) facility consolidation, optimization, manufacturing transfer and system integration charges,

1. asset write-down and disposition charges, (v) charges in connection with corporate realignments or a reduction in force, (vi) certain litigation expenses, charges and gains, (vii) unusual or infrequently occurring items, (viii) gain/loss on cost and equity method investments, (ix) extinguishment of debt charges,
2. the net impact of Long-term Supply Agreements (“LSAs”) between the Company and Viant, (xi) the income tax (benefit) related to these adjustments and
3. certain tax items that are outside the normal provision for the period (not for adjusted pre-tax income). Adjusted earnings per diluted share are calculated by dividing adjusted income from continuing operations by diluted weighted average shares outstanding. Adjusted EBITDA from continuing operations consists of GAAP net income (loss) from continuing operations plus (i) the same adjustments as listed above except for items (xi) and (xii), (ii) GAAP stock-based compensation, interest expense, and depreciation and (iii) GAAP provision (benefit) for income taxes. To calculate organic sales growth rates, which exclude the impact of changes in foreign currency exchange rates, as well as the impact of any acquisitions or divestitures of product lines on sales growth rates, we convert current period sales from local currency to U.S. dollars using the previous periods foreign currency exchange rates and exclude the amount of sales acquired/divested during the period from the current/previous period amounts, respectively. We believe that the presentation of adjusted income, adjusted diluted earnings per share, EBITDA, adjusted EBITDA, and organic sales growth rates, all from continuing operations, provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations.
   * 37 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**MANAGEMENT'S DISCUSSION AND ANALYSIS**

***Income (Loss) from Continuing Operations and Diluted EPS Reconciliations***

A reconciliation of GAAP income from continuing operations and diluted earnings per share (“EPS”) from continuing operations to adjusted amounts is as follows (in thousands, except per share amounts):

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  | **Three Months Ended** | | | | | |  |  |  |  |  |
|  |  |  | | | | | |  |  |  |  | | | | | |  |
|  |  | **September 28, 2018** | | | | | |  |  |  | **September 29, 2017** | | | | | |  |
|  |  |  | |  |  |  |  |  |  |  |  | |  |  |  |  |  |
|  |  | **Pre-Tax** | |  |  |  |  | **Per** | |  | **Pre-Tax** | |  |  |  |  | **Per** |
|  |  | **Income** | |  | **Income** | | **Diluted** | | |  | **Income** | |  | **Income** | | **Diluted** | |
|  |  | **(Loss)** | |  | **(Loss)** | |  | **Share** | |  | **(Loss)** | |  | **(Loss)** | |  | **Share** |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| As reported income from continuing operations (GAAP) | $ | (14,460) |  | $ | (8,303) |  | $ | (0.26) |  | $ | 19,434 |  | $ | 19,882 |  | $ | 0.62 |
| Adjustments: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Amortization of intangibles(a) |  | 9,896 |  |  | 7,830 |  |  | 0.24 |  |  | 10,145 |  |  | 7,103 |  |  | 0.22 |
| IP related litigation (SG&A)(a)(b) |  | 749 |  |  | 591 |  |  | 0.02 |  |  | 1,735 |  |  | 1,128 |  |  | 0.04 |
| Strategic reorganization and alignment (OOE)(a)(c) |  | 2,643 |  |  | 2,085 |  |  | 0.06 |  |  | — | |  | — | |  | — |
| Manufacturing alignment to support growth (OOE)(a)(d) |  | 877 |  |  | 657 |  |  | 0.02 |  |  | — | |  | — | |  | — |
| Consolidation and optimization expenses (OOE)(a)(e) |  | 137 |  |  | 108 |  |  | — | |  | 2,979 |  |  | 2,630 |  |  | 0.08 |
| Acquisition and integration expenses (OOE)(a)(f) |  | — | |  | — | |  | — | |  | 2,267 |  |  | 1,106 |  |  | 0.03 |
| Asset dispositions, severance and other (OOE)(a)(g) |  | 482 |  |  | 412 |  |  | 0.01 |  |  | 823 |  |  | 546 |  |  | 0.02 |
| (Gain) loss on cost and equity method investments, net(a) |  | (291) |  |  | (230) |  |  | (0.01) |  |  | (1,906) |  |  | (1,239) |  |  | (0.04) |
| Loss on extinguishment of debt(a)(h) |  | 40,654 |  |  | 32,117 |  |  | 0.98 |  |  | 778 |  |  | 506 |  |  | 0.02 |
| LSA adjustments(a)(i) |  | — | |  | — | |  | — | |  | (3,450) |  |  | (2,242) |  |  | (0.07) |
| Tax adjustments(j) |  | — | |  | (417) |  |  | (0.01) |  |  | — | |  | — | |  | — |
| Adjusted income from continuing operations (Non-GAAP) | $ | 40,687 |  | $ | 34,850 |  | $ | 1.06 |  | $ | 32,805 |  | $ | 29,420 |  | $ | 0.91 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Diluted weighted average shares for adjusted EPS |  |  |  |  | 32,899 |  |  |  |  |  |  |  |  | 32,173 |  |  |  |
|  |  |  |  |  |  |  |  | |  | | |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  | |  | | |  |  |  |  |  |  |
|  |  |  |  |  |  |  | **Nine Months Ended** | | | | | |  |  |  |  |  |
|  |  |  | | | | | |  |  |  |  | | | | | |  |
|  |  | **September 28, 2018** | | | | | |  |  |  | **September 29, 2017** | | | | | |  |
|  |  |  | |  |  |  |  |  |  |  |  | |  |  |  |  |  |
|  |  | **Pre-Tax** | |  |  |  |  | **Per** | |  | **Pre-Tax** | |  |  |  |  | **Per** |
|  |  | **Income** | |  | **Income** | | **Diluted** | | |  | **Income** | |  | **Income** | | **Diluted** | |
|  |  | **(Loss)** | |  | **(Loss)** | |  | **Share** | |  | **(Loss)** | |  | **(Loss)** | |  | **Share** |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| As reported income from continuing operations (GAAP) | $ | 35,793 |  | $ | 27,837 |  | $ | 0.86 |  | $ | 32,985 |  | $ | 32,389 |  | $ | 1.01 |
| Adjustments: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Amortization of intangibles(a) |  | 31,068 |  |  | 24,523 |  |  | 0.75 |  |  | 30,375 |  |  | 21,205 |  |  | 0.66 |
| IP related litigation (SG&A)(a)(b) |  | 1,546 |  |  | 1,221 |  |  | 0.04 |  |  | 3,027 |  |  | 1,968 |  |  | 0.06 |
| Strategic reorganization and alignment (OOE)(a)(c) |  | 8,424 |  |  | 6,662 |  |  | 0.20 |  |  | — | |  | — | |  | — |
| Manufacturing alignment to support growth (OOE)(a)(d) |  | 2,493 |  |  | 1,841 |  |  | 0.06 |  |  | — | |  | — | |  | — |
| Consolidation and optimization expenses (OOE)(a)(e) |  | 698 |  |  | 553 |  |  | 0.02 |  |  | 8,055 |  |  | 6,525 |  |  | 0.20 |
| Acquisition and integration expenses (OOE)(a)(f) |  | — | |  | — | |  | — | |  | 10,057 |  |  | 6,276 |  |  | 0.20 |
| Asset dispositions, severance and other (OOE)(a)(g) |  | 1,000 |  |  | 776 |  |  | 0.02 |  |  | 6,378 |  |  | 4,144 |  |  | 0.13 |
| (Gain) loss on cost and equity method investments, net(a) |  | (5,545) |  |  | (4,381) |  |  | (0.13) |  |  | 2,919 |  |  | 1,897 |  |  | 0.06 |
| Loss on extinguishment of debt(a)(h) |  | 42,128 |  |  | 33,281 |  |  | 1.02 |  |  | 3,272 |  |  | 2,127 |  |  | 0.07 |
| LSA adjustments(a)(i) |  | (6,119) |  |  | (4,834) |  |  | (0.15) |  |  | (9,361) |  |  | (6,084) |  |  | (0.19) |
| Tax adjustments(j) |  | — | |  | 2,534 |  |  | 0.08 |  |  | — | |  | — | |  | — |
| Adjusted income from continuing operations (Non-GAAP) | $ | 111,486 |  | $ | 90,013 |  | $ | 2.75 |  | $ | 87,707 |  | $ | 70,447 |  | $ | 2.21 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Diluted weighted average shares for adjusted EPS |  |  |  |  | 32,681 |  |  |  |  |  |  |  |  | 31,947 |  |  |  |

- 38 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**MANAGEMENT'S DISCUSSION AND ANALYSIS**

1. The difference between pre-tax and income (loss) amounts is the estimated tax impact related to the respective adjustment. Income (loss) amounts are computed using a 21% U.S. tax rate (35% U.S. tax rate for 2017 periods), and the statutory tax rates in Mexico, Netherlands, Uruguay, Ireland and Switzerland, as adjusted for the existence of NOLs. Amortization of intangibles and OOE expense have also been adjusted to reflect the estimated impact relating to our disallowed deduction of the GILTI tax, as described in footnote (j) below. Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%.
2. In 2013, we filed suit against AVX Corporation alleging they were infringing our intellectual property. Given the complexity and significant costs incurred pursuing this litigation, we are excluding these litigation expenses from adjusted amounts. This matter proceeded to trial during the first quarter of 2016 and again in the third quarter of 2017 that resulted in a jury awarding damages in the amount of $37.5 million. In March 2018, the court vacated that damage award and ordered a new trial on damages, which is scheduled for January 2019. To date, no gains have been recognized in connection with this litigation.
3. As a result of the strategic review of our customers, competitors and markets we undertook during the fourth quarter of 2017, we began to take steps to better align our resources in order to invest to grow, protect, preserve and to enhance the profitability of our portfolio of products. This will include focusing our investment in RD&E and manufacturing, improving our business processes and redirecting investments away from projects where the market does not justify the investment. As a result, during 2018 we incurred charges related to this strategy, which primarily consisted of severance costs and fees for professional services.
4. In 2017, we initiated several initiatives designed to reduce costs, improve operating efficiencies and increase manufacturing capacity to accommodate growth. The plan involves the relocation of certain manufacturing operations and expansion of certain of our facilities.
5. During 2018 and 2017, we incurred costs primarily related to the closure of our Clarence, NY facility and the transfer of our Beaverton, OR portable medical and Plymouth, MN vascular manufacturing operations to Tijuana, Mexico.
6. Reflects acquisition and integration costs related to the acquisition of Lake Region Medical, which occurred in October 2015.
7. Amounts for 2017 primarily include expenses related to our CEO and CFO transitions.
8. Represents debt extinguishment charges in connection with pre-payments made on our Term B Loan Facility and Senior Notes, which are included in interest expense. In addition, the 2018 periods include a “make-whole” premium of $31.3 million, paid as a result of redeeming our Senior Notes in July 2018.
9. Reflects the net impact of the LSAs entered into as of the closing of the divestiture of the AS&O Product Line. These LSAs govern the sale of products supplied by Viant to the Company for further resale to customers and by the Company to Viant for further resale to customers.
10. Tax adjustments primarily includes the estimated impact relating to our disallowed deduction of the GILTI tax, as mandated by the Tax Reform Act. This disallowed deduction of the GILTI tax (approximately 50% of the total GILTI tax) is due to the Company making use of its U.S. NOLs, and will be eliminated once the Company’s U.S. NOLs are fully utilized, which is expected to be in 2019. This adjustment makes our Adjusted Diluted EPS from continuing operations more comparable with other global companies that are not subject to this disallowed GILTI tax deduction and more comparable to the Company’s results following the full utilization of its U.S. NOLs.
    * 39 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**MANAGEMENT'S DISCUSSION AND ANALYSIS**

Adjusted diluted EPS from continuing operations, which excludes the impact of amortization of intangible assets, losses on extinguishment of debt and various other operating expenses, among others, was $1.06 and $2.75 per share for the third quarter and first nine months of 2018, respectively, compared to $0.91 and $2.21 per share for the third quarter and first nine months of 2017, respectively. These results reflect the benefit of our increased sales and the completion of spending on integration activities, partially offset by higher incentive compensation and higher interest expense in 2018 compared to 2017.

***EBITDA and Adjusted EBITDA Reconciliation***

A reconciliation of GAAP income from continuing operations to EBITDA from continuing operations and adjusted EBITDA from continuing operations is as follows (dollars in thousands):

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended** | | | | |  | **Nine Months Ended** | | | |  |
|  |  |  | |  |  |  |  |  | |  |  |  |
|  |  | **September 28,** | |  | **September 29,** | |  | **September 28,** | |  | **September 29,** |  |
|  |  | **2018** |  |  | **2017** |  |  | **2018** |  |  | **2017** |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Income (loss) from continuing operations (GAAP) | $ | (8,303) |  | $ | 19,882 |  | $ | 27,837 |  | $ | 32,389 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Interest expense |  | 54,526 |  |  | 15,808 |  |  | 85,355 |  |  | 49,233 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Provision for income taxes |  | (6,157) |  |  | (448) |  |  | 7,956 |  |  | 596 |  |
| Depreciation |  | 9,960 |  |  | 9,534 |  |  | 29,929 |  |  | 28,262 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Amortization |  | 9,896 |  |  | 10,145 |  |  | 31,068 |  |  | 30,375 |  |
| EBITDA from continuing operations |  | 59,922 |  |  | 54,921 |  |  | 182,145 |  |  | 140,855 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| IP related litigation |  | 749 |  |  | 1,735 |  |  | 1,546 |  |  | 3,027 |  |
| Stock-based compensation (excluding OOE) |  | 2,087 |  |  | 2,041 |  |  | 7,265 |  |  | 7,116 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Strategic reorganization and alignment |  | 2,643 |  |  | — | |  | 8,424 |  |  | — |  |
| Manufacturing alignment to support growth |  | 877 |  |  | — | |  | 2,493 |  |  | — |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Consolidation and optimization expenses |  | 137 |  |  | 2,979 |  |  | 698 |  |  | 8,055 |  |
| Acquisition and integration expenses |  | — | |  | 2,267 |  |  | — | |  | 10,057 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Asset dispositions, severance and other |  | 482 |  |  | 823 |  |  | 1,000 |  |  | 6,378 |  |
| Non-cash (gain) loss on cost and equity |  |  |  |  |  |  |  |  |  |  |  |  |
| method investments |  | (291) |  |  | (992) |  |  | (5,545) |  |  | 3,833 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| LSA adjustments | $ | — | | $ | (3,450) |  | $ | (6,119) |  | $ | (9,361) |  |
| Adjusted EBITDA from continuing operations | $ | 66,606 |  | $ | 60,324 |  | $ | 191,907 |  | $ | 169,960 |  |
| (Non-GAAP) |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |

**Our CEO’s View**

We delivered another solid quarter of sales growth, leading to another increase in our revenue and EPS guidance. We also reduced our debt dramatically during the quarter and lowered our debt leverage ratio from the beginning of the year.

At the beginning of the fourth quarter we hired Jason Garland as our new Executive Vice President and Chief Financial Officer. Jason brings nearly 25 years of public company, global financial leadership experience and significant manufacturing and customer contract expertise to Integer.

With the executive leadership team in place, we are focused on executing our portfolio strategy to win in the markets we serve and our operational strategy to achieve excellence in everything we do. We remain in a strong position to deliver on our long-term objectives of sales growth above the market, profit growth two times sales growth, and earning a valuation premium.

- 40 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**MANAGEMENT'S DISCUSSION AND ANALYSIS**

**Cost Savings and Consolidation Efforts**

In 2018 and 2017, we recorded charges in Other Operating Expenses related to various cost savings and consolidation initiatives. These initiatives were undertaken to improve our operational efficiencies and profitability, the most significant of which are as follows (dollars in millions):

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  | **Expected** | | | **Expected** | | |  |
|  |  | **Expected** | | **Capital** | | | **Annual Cost** | | | **Expected** |
| **Initiative** |  | **Expense** |  | **Expenditures** | |  | **Savings(a)** | |  | **Completion Date** |
| Strategic reorganization and alignment | | $28 - $30(b) | |  | - |  | $8 - $12 | |  | 2018 |
| Manufacturing alignment to support growth | | $9 - $11 |  | $4 | - $6 |  | $2 | - $3 |  | 2019 |
|  |  |  |  |  |  |  |  |  |  |  |
| Consolidation and optimization expenses | | $18 - $22(b) | | $5 | - $6 |  | $12 | - $13 |  | 2018 |

1. Represents the annual benefit to our operating income expected to be realized from these initiatives through cost savings and/or increased capacity. These benefits will be phased in over time as the various initiatives are completed, some of which are already included in our current period results.
2. Expected expense for these initiatives include amounts classified as discontinued operations.

We continually evaluate our operating structure in order to maximize efficiencies and drive margin expansion. Future charges are expected to be incurred as we seek to create an optimized manufacturing footprint, leveraging our increased scale and product capabilities while also supporting the needs of our customers. Our efforts will include:

* potential manufacturing consolidations;
* continuous improvement;
* productivity initiatives;
* direct material and indirect expense savings opportunities; and
* the establishment of centers of excellence.

Refer to Note 8 “Other Operating Expenses” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about the timing, cash flow impact, and amount of future expenditures for our cost savings and consolidation initiatives.

- 41 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**MANAGEMENT'S DISCUSSION AND ANALYSIS**

**Our Financial Results of Continuing Operations**

We utilize a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. For 52-week years, each quarter contains 13 weeks. The third quarter and first nine months of 2018 and 2017 ended on September 28 and September 29, respectively, and each contained 13 weeks and 26 weeks, respectively.

The following tables present selected financial information from continuing operations derived from our Condensed Consolidated Financial Statements, contained in Item 1 of this report, for the periods presented (dollars in thousands, except per share). All financial information presented is from continuing operations unless otherwise specified.

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended** | | | | |  |  |  |  |  |
|  |  |  | |  |  |  |  |  | | |  |
|  |  | **September 28,** | |  | **September 29,** | |  | **Change** | | |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **2018** |  |  | **2017** |  |  | **$** |  |  | **%** |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Medical Sales:** |  |  |  |  |  |  |  |  |  |  |  |
| Cardio & Vascular | $ | 150,230 |  | $ | 137,712 |  | $ | 12,518 |  |  | 9.1 % |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Cardiac & Neuromodulation |  | 109,620 |  |  | 101,612 |  |  | 8,008 |  |  | 7.9 % |
| Advanced Surgical, Orthopedics & Portable Medical |  | 32,789 |  |  | 31,715 |  |  | 1,074 |  |  | 3.4 % |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Total Medical Sales |  | 292,639 |  |  | 271,039 |  |  | 21,600 |  |  | 8.0 % |
| **Non-Medical** |  | 12,449 |  |  | 15,129 |  |  | (2,680) |  |  | (17.7)% |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Total Sales |  | 305,088 |  |  | 286,168 |  |  | 18,920 |  |  | 6.6 % |
| Cost of sales |  | 213,165 |  |  | 196,982 |  |  | 16,183 |  |  | 8.2 % |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Gross profit |  | 91,923 |  |  | 89,186 |  |  | 2,737 |  |  | 3.1 % |
| *Gross profit as a % of sales* |  | *30.1 %* |  |  | *31.2 %* |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| SG&A |  | 34,091 |  |  | 35,064 |  |  | (973) |  |  | (2.8)% |
| *SG&A as a % of sales* |  | *11.2 %* |  |  | *12.3 %* |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| RD&E |  | 12,234 |  |  | 12,227 |  |  | 7 |  |  | 0.1 % |
| *RD&E as a % of sales* |  | *4.0 %* |  |  | *4.3 %* |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Other operating expenses |  | 4,139 |  |  | 6,069 |  |  | (1,930) |  |  | (31.8)% |
| Operating income |  | 41,459 |  |  | 35,826 |  |  | 5,633 |  |  | 15.7 % |
|  |  |  |  |  |  |  |  |  |  |  |  |
| *Operating margin* |  | *13.6 %* |  |  | *12.5 %* |  |  |  |  |  |  |
| Interest expense |  | 54,526 |  |  | 15,808 |  |  | 38,718 |  |  | NM |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Gain on cost and equity method investments, net |  | (291) |  |  | (1,906) |  |  | 1,615 |  |  | (84.7)% |
| Other loss, net |  | 1,684 |  |  | 2,490 |  |  | (806) |  |  | (32.4)% |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Income (loss) from continuing operations before income taxes |  | (14,460) |  |  | 19,434 |  |  | (33,894) |  |  | NM |
| Benefit for income taxes |  | (6,157) |  |  | (448) |  |  | (5,709) |  |  | NM |
|  |  |  |  |  |  |  |  |  |  |  |  |
| *Effective tax rate* |  | *42.6 %* |  |  | *(2.3)%* |  |  |  |  |  |  |
| Income (loss) from continuing operations | $ | (8,303) |  | $ | 19,882 |  | $ | (28,185) |  |  | NM |
|  |  |  |  |  |  |  |  |  |  |  |  |
| *Income (loss) from continuing operations as a % of sales* |  | *(2.7)%* |  |  | *6.9 %* |  |  |  |  |  |  |
| Diluted earnings (loss) per share from continuing operations | $ | (0.26) |  | $ | 0.62 |  | $ | (0.88) |  |  | NM |
| - 42 - | | |  |  |  |  |  |  |  |  |  |

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**MANAGEMENT'S DISCUSSION AND ANALYSIS**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Nine Months Ended** | | | | |  |  |  |  |  |
|  |  |  | |  |  |  |  |  | | |  |
|  |  | **September 28,** | |  | **September 29,** | |  | **Change** | | |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **2018** |  |  | **2017** |  |  | **$** |  |  | **%** |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Medical Sales:** |  |  |  |  |  |  |  |  |  |  |  |
| Cardio & Vascular | $ | 435,859 |  | $ | 391,914 |  | $ | 43,945 |  |  | 11.2 % |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Cardiac & Neuromodulation |  | 334,471 |  |  | 311,540 |  |  | 22,931 |  |  | 7.4 % |
| Advanced Surgical, Orthopedics & Portable Medical |  | 101,481 |  |  | 88,148 |  |  | 13,333 |  |  | 15.1 % |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Total Medical Sales |  | 871,811 |  |  | 791,602 |  |  | 80,209 |  |  | 10.1 % |
| **Non-Medical** |  | 40,167 |  |  | 42,218 |  |  | (2,051) |  |  | (4.9)% |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Total Sales |  | 911,978 |  |  | 833,820 |  |  | 78,158 |  |  | 9.4 % |
| Cost of sales |  | 637,758 |  |  | 573,431 |  |  | 64,327 |  |  | 11.2 % |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Gross profit |  | 274,220 |  |  | 260,389 |  |  | 13,831 |  |  | 5.3 % |
| *Gross profit as a % of sales* |  | *30.1%* |  |  | *31.2%* |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| SG&A |  | 107,300 |  |  | 105,004 |  |  | 2,296 |  |  | 2.2 % |
| *SG&A as a % of sales* |  | *11.8%* |  |  | *12.6%* |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| RD&E |  | 38,445 |  |  | 35,104 |  |  | 3,341 |  |  | 9.5 % |
| *RD&E, Net as a % of sales* |  | *4.2%* |  |  | *4.2%* |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Other operating expenses |  | 12,615 |  |  | 24,490 |  |  | (11,875) |  |  | (48.5)% |
| Operating income |  | 115,860 |  |  | 95,791 |  |  | 20,069 |  |  | 21.0 % |
|  |  |  |  |  |  |  |  |  |  |  |  |
| *Operating margin* |  | *12.7%* |  |  | *11.5%* |  |  |  |  |  |  |
| Interest expense |  | 85,355 |  |  | 49,233 |  |  | 36,122 |  |  | 73.4 % |
|  |  |  |  |  |  |  |  |  |  |  |  |
| (Gain) loss on cost and equity method investments, net |  | (5,545) |  |  | 2,919 |  |  | (8,464) |  |  | NM |
| Other loss, net |  | 257 |  |  | 10,654 |  |  | (10,397) |  |  | (97.6)% |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Income from continuing operations before income taxes |  | 35,793 |  |  | 32,985 |  |  | 2,808 |  |  | 8.5 % |
| Provision for income taxes |  | 7,956 |  |  | 596 |  |  | 7,360 |  |  | NM |
|  |  |  |  |  |  |  |  |  |  |  |  |
| *Effective tax rate* |  | *22.2%* |  |  | *1.8%* |  |  |  |  |  |  |
| Income from continuing operations | $ | 27,837 |  | $ | 32,389 |  | $ | (4,552) |  |  | (14.1)% |
| *Income from continuing operations as a % of sales* |  | *3.1%* |  |  | *3.9%* |  |  |  |  |  |  |
| Diluted earnings per share from continuing operations | $ | 0.86 |  | $ | 1.01 |  | $ | (0.15) |  |  | (14.9)% |
| NM Calculated amount not meaningful |  |  |  |  |  |  |  |  |  |  |  |
| - 43 - | | |  |  |  |  |  |  |  |  |  |

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**MANAGEMENT'S DISCUSSION AND ANALYSIS**

**Product Line Sales of Continuing Operations Highlights**

For the third quarter and first nine months of 2018, Cardio & Vascular sales increased $12.5 million, or 9% and $43.9 million or 11%, respectively, versus the comparable 2017 periods. These increases were primarily due to continued strong demand in the electrophysiology market stemming from customer share gains, new product launches, and timing from customer inventory replenishment. The Cardio & Vascular growth trend is expected to remain above market from increased focus on high growth market segments. Foreign currency exchange rate fluctuations decreased Cardio & Vascular sales for the three months ended September 28, 2018 by $0.1 million and increased Cardio & Vascular sales by $2.3 million for the nine months ended September 28, 2018, respectively, in comparison to the 2017 periods primarily due to U.S. dollar fluctuations relative to the Euro.

For the third quarter and first nine months of 2018, Cardiac & Neuromodulation sales increased $8.0 million, or 8% and $22.9 million, or 7%, respectively, versus the comparable 2017 periods. The increases in Cardiac & Neuromodulation sales were driven by increased components market penetration and lower 2017 comparables from customer inventory adjustments. Neuromodulation remained strong, with growth driven by spinal cord stimulation market demand and increased components market penetration. Cardiac & Neuromodulation sales are expected to decrease in the fourth quarter of 2018 compared to extremely strong fourth quarter of 2017. Foreign currency exchange rate fluctuations did not have a material impact on Cardiac & Neuromodulation sales during the 2018 periods in comparison to the same periods of 2017.

Advanced Surgical, Orthopedic & Portable Medical includes sales to the acquirer of our AS&O Product Lines, Viant, under supply agreements associated with the divestiture. For the third quarter and first nine months of 2018, AS&O sales increased $1.1 million, or 3%, and $13.3 million, or 15%, respectively, versus the comparable 2017 periods. The sales increase was driven by above market demand. Sales are expected to level off from strong first half and growth is expected to be more in line with the overall market. Foreign currency exchange rate fluctuations did not have a material impact on AS&O sales during the 2018 periods in comparison to the same periods of 2017.

For the third quarter and first nine months of 2018, Non-Medical sales decreased $2.7 million, or 18% and $2.1 million, or 5%, respectively, versus the comparable 2017 periods. The decline in Non-Medical sales was primarily due to North American drilling activity leveling off which has led to customer inventory adjustments. The quarter was also impacted by a planned phase out of certain rechargeable battery pack products. We expect fourth quarter 2018 year-over-year sales to be flat and we expect solid sales growth in 2019 from new customers and products, and renewed military market government funding. Foreign currency exchange rate fluctuations did not have a material impact on Non-Medical sales during the 2018 periods in comparison to the same periods of 2017.

***Gross Profit***

Changes to gross profit as a percentage of sales (“Gross Margin”) from the prior year were due to the following:

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Change From Prior Year** | | |
|  |  | |  |
|  | **Three** | | **Nine** |
|  | **Months** | | **Months** |
|  |  |  |  |
| Price(a) | (1.4)% |  | (1.3)% |
| Mix(b) | — | | (0.2) |
| Incentive compensation(c) | (0.7) |  | (0.6) |
| Production efficiencies and volume(d) | 1.0 |  | 1.0 |
| Total percentage point change to gross profit as a percentage of sales | (1.1)% |  | (1.1)% |
|  |  |  |  |

1. Our Gross Margin for the third quarter and first nine months of 2018 has been negatively impacted by price concessions given to our larger OEM customers in return for long-term volume commitments.
2. Our Gross Margin for the first nine months of 2018 has been negatively impacted by a higher mix of sales of lower margin products.
3. Amounts represent the impact to our Gross Margin attributable to our cash and stock incentive programs, including performance-based compensation, which is accrued based upon actual results achieved.
4. Represents various increases and decreases to our Gross Margin. Overall, our Gross Margin for the third quarter and first nine months of 2018 has been positively impacted by production efficiencies and synergies gained as a result of our integration and consolidation initiatives as well as higher volume in comparison to the respective 2017 period.
   * 44 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**MANAGEMENT'S DISCUSSION AND ANALYSIS**

***SG&A Expenses***

Changes to SG&A expenses from the prior year were due to the following (in thousands):

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | **Change From Prior Year** | | | |
|  |  |  | |  |  |
|  |  | **Three** | |  | **Nine** |
|  |  | **Months** | |  | **Months** |
|  |  |  |  |  |  |
| Legal expenses(a) | $ | (838) |  | $ | (1,358) |
| Intangible asset amortization(b) |  | 268 |  |  | 1,512 |
| Incentive compensation programs(c) |  | 1,884 |  |  | 5,111 |
| Transition services agreement(d) |  | (1,834) |  |  | (1,834) |
| Other(e) |  | (453) |  |  | (1,135) |
| Net increase (decrease) in SG&A Expenses | $ | (973) |  | $ | 2,296 |
|  |  |  |  |  |  |

1. Amount represents the change in legal costs compared to the prior year period, including legal expenses incurred related to our on-going patent infringement case. Refer to Note 10 “Commitments and Contingencies” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for information related to this patent infringement litigation.
2. Amount represents the increase in intangible asset amortization (i.e. customer list), which is amortized based upon the forecasted cash flows at the time of acquisition for the respective asset.
3. Amount represents the impact to our SG&A attributable to our cash and stock incentive programs, including performance-based compensation, which is accrued based upon actual results achieved.
4. Represents the amount included in SG&A Expenses, which was charged to Viant for transition services provided for the three months ended September 28, 2018. We executed a transition services agreement in conjunction with the sale of the AS&O Product Line, whereby we will provide certain corporate services (including accounting, payroll, and information technology services) to Viant for a period of up to one year from the date of the closing to facilitate an orderly transfer of business operations.
5. Represents various increases and decreases to our SG&A.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| ***RD&E*** |  |  |  |  |  |
| Changes to RD&E expenses from the prior year were due to the following (in thousands): |  |  |  |  |  |
|  | **Change From Prior Year** | | | | |
|  |  |  |  |  |  |
|  | **Three** |  |  |  | **Nine** |
|  | **Months** |  |  |  | **Months** |
|  |  |  |  |  |  |
| Intangible asset amortization(a) | $ | (98) |  | $ | (293) |
| Incentive compensation programs(b) |  | 389 |  |  | 1,120 |
| Other(c) |  | (284) |  |  | 2,514 |
| Net increase in RD&E | $ | 7 |  | $ | 3,341 |
|  |  |  |  |  |  |

1. Amount represents the decrease in intangible asset amortization, which is amortized based upon the forecasted cash flows at the time of acquisition for the respective asset.
2. Amount represents the impact to our RD&E attributable to our cash and stock incentive programs, including performance-based compensation, which is accrued based upon actual results achieved.
3. Represents the net impact of various increases and decreases to our RD&E. RD&E expense for the third quarter and first nine months of 2018 reflects our increased investment in projects with a higher growth opportunity.
   * 45 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**MANAGEMENT'S DISCUSSION AND ANALYSIS**

***Other Operating Expenses***

Refer to “Cost Savings and Consolidation Efforts” section of this Item and Note 8 “Other Operating Expenses” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for further information related to these initiatives. Other Operating Expenses is comprised of the following (in thousands):

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended** | | | | |  | **Nine Months Ended** | | | |
|  |  |  | |  |  |  |  |  | |  |  |
|  |  | **September 28,** | |  | **September 29,** | |  | **September 28,** | |  | **September 29,** |
|  |  | **2018** |  |  | **2017** |  |  | **2018** |  |  | **2017** |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Strategic reorganization and alignment(a) | $ | 2,643 |  | $ | — | | $ | 8,424 |  | $ | — |
| Manufacturing alignment to support growth(b) |  | 877 |  |  | — | |  | 2,493 |  |  | — |
| Consolidation and optimization costs(c) |  | 137 |  |  | 2,979 |  |  | 698 |  |  | 8,055 |
| Acquisition and integration expenses(d) |  | — | |  | 2,267 |  |  | — | |  | 10,057 |
| Asset dispositions, severance and other(e) |  | 482 |  |  | 823 |  |  | 1,000 |  |  | 6,378 |
| Total other operating expenses | $ | 4,139 |  | $ | 6,069 |  | $ | 12,615 |  | $ | 24,490 |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |

1. As a result of the strategic review of our customers, competitors and markets we undertook during the fourth quarter of 2017, we began to take steps to better align our resources in order to invest to grow, protect, preserve and to enhance the profitability of our portfolio of products. This will include focusing our investment in RD&E and manufacturing, improving our business processes and redirecting investments away from projects where the market does not justify the investment. As a result, during the first nine months of 2018, we incurred charges related to this strategy, which primarily included severance costs and fees for professional services.
2. In 2017, we initiated several initiatives designed to reduce costs, improve operating efficiencies and increase manufacturing capacity to accommodate growth. The plan involves the relocation of certain manufacturing operations and expansion of certain of our facilities.
3. During 2018 and 2017, we incurred costs primarily related to the closure of our Clarence, NY facility and the transfer of our Beaverton, OR portable medical and Plymouth, MN vascular manufacturing operations to Tijuana, Mexico.
4. Reflects acquisition and integration costs related to the acquisition of Lake Region Medical, which occurred in October 2015. This initiative was substantially complete as of December 29, 2017.
5. Amounts for 2017 primarily include expenses related to our CEO and CFO transitions.

We continually evaluate our operating structure in order to maximize efficiencies and drive margin expansion. For 2018, Other Operating Expenses is expected to be approximately $15 million to $20 million. Refer to the “Cost Savings and Consolidation Efforts” section of this Item for further details on these initiatives.

- 46 -

***Interest Expense***

Interest Expense for the three and nine months ended September 28, 2018 was $54.5 million and $85.4 million, respectively, compared to $15.8 million and $49.2 million for the three and nine months ended September 29, 2017. The weighted average interest rates paid on outstanding borrowings for the three and nine months ended September 28, 2018 was 4.95% and 4.97%, respectively, compared to 4.72% and 4.67%, for the comparable periods in 2017. The weighted average interest rates paid in the third quarter and first nine months of 2018 reflect an increase in LIBOR during 2017 and 2018, partially offset by a cumulative 125 basis point and 75 basis point reduction to the applicable interest rate margins of our Term Loan B and Term Loan A facilities. The Term Loan B margin decrease resulted from amendments of our Senior Secured Credit Facilities in March 2017 and again in November 2017, and the step down in the third quarter of 2018 resulting from the upgrade of our corporate family credit rating, while the Term Loan A decrease resulted from contractual reductions due to our lower leverage ratio. Cash interest expense decreased $1.1 million and $2.4 million for the three and nine months ended September 28, 2018, respectively, when compared to the same periods in 2017. Non-cash interest expense (i.e. deferred fee and discount amortization) increased $39.8 million and $38.6 million for the three and nine months ended September 28, 2018, respectively, when compared to the same period in 2017, primarily attributable to higher accelerated write-offs (losses from extinguishment of debt) of deferred fees and original issue discount related to prepayments of portions of our Term Loan B facility and Senior Notes during the respective periods and a “make-whole” premium of $31.3 million paid as a result of redeeming our Senior Notes in July 2018. We recognized losses from extinguishment of debt during the three and nine months ended September 28, 2018 of $40.7 million and $42.1 million, respectively. We repaid $595.0 million of debt during the third quarter of 2018 and $670.1 million during the first nine months of 2018. See Note 5 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our debt.

***(Gain) Loss on Cost and Equity Method Investments, Net***

The Company holds investments in equity and other securities that are accounted for as either cost method or equity method investments. During the three and nine months ended September 28, 2018, we recognized net gains of $0.3 million and $5.5 million, respectively, compared to a net gain of $1.9 million and a net loss of $2.9 million for the three and nine months ended September 29, 2017, respectively, on our cost and equity method investments. The Company did not recognize any impairment charges related to cost method investments during the nine months ended September 28, 2018. The three and nine months ended September 29, 2017 included impairment charges of $0.3 million and $5.3 million, respectively, recognized on our cost method investments. Our cost method investments are in start-up research and development companies whose fair value is highly subjective in nature and could be subject to significant fluctuations in the future that could result in material gains or losses. See Note 13 “Fair Value Measurements” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our cost and equity method investments.

***Other Loss, Net***

Other Loss, Net for the three and nine months ended September 28, 2018 was $1.7 million and $0.3 million, respectively, compared to other loss of $2.5 million and $10.7 million for the three and nine months ended September 29, 2017. Other Loss, Net is primarily comprised of income (loss) from the impact of foreign currency exchange rates on transactions denominated in foreign currencies.

Our foreign currency transaction gains/losses are based on fluctuations of the U.S. dollar relative to the Euro or Peso. The impact of foreign currency

exchange rates on transactions denominated in foreign currencies included in Other Loss, Net for the three and nine months ended September 28, 2018 were

losses of $1.7 million and $0.8 million, respectively, compared to a losses of $2.5 million and $10.6 million for the three and nine months ended

September 29, 2017, respectively. We continually monitor our foreign currency exposures and seek to take steps to mitigate these risks. However, fluctuations

in foreign currency exchange rates could have a significant impact, positive or negative, on our financial results in the future.

***Provision for Income Taxes***

We recognized income tax benefit of $6.2 million for the third quarter of 2018 on $14.5 million of pre-tax loss from continuing operations compared to income tax benefit of $0.4 million on $19.4 million of pre-tax income from continuing operations for the same period of 2017. The income tax expense for the first nine months of 2018 was $7.9 million on income from continuing operations before taxes of $35.8 million compared to $0.6 million on $33.0 million of income from continuing operations before taxes for the same period of 2017.

- 47 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**MANAGEMENT'S DISCUSSION AND ANALYSIS**

We expect continued volatility in our effective tax rate due to several factors including: changes in the mix of pre-tax income from continuing operations and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. We continuously evaluate and currently have various tax planning initiatives in place that are aimed at reducing our effective tax rate over the long term.

Our worldwide effective tax rate is expected to be approximately 32% for 2018, excluding discrete items. Our effective tax rate for 2018 differs from the U.S. federal statutory tax rate of 21% due principally to the estimated impact of the GILTI tax. Our earnings outside the U.S. are generally taxed at blended rates that are marginally lower than the U.S. federal rate. The GILTI provisions require us to include foreign subsidiary earnings in excess of a deemed return on the foreign subsidiary’s tangible assets in our U.S. income tax return. There is a statutory deduction of 50% of the GILTI inclusion, however the deduction is subject to limitations based on U.S. taxable income. We currently have NOLs to offset forecasted U.S. taxable income and as such, are temporarily subject to the deduction limitation, which correspondingly imposes an incremental impact on U.S. income tax. The foreign jurisdictions in which we operate and where our foreign earnings are primarily derived, include Switzerland, Mexico, Uruguay, Malaysia and Ireland. While we are not currently aware of any material trends in these jurisdictions that are likely to impact our current or future tax expense, our future effective tax rates could be adversely affected by earnings being lower than anticipated in countries where we have lower effective tax rates and higher than anticipated in countries where we have higher effective tax rates, or by changes in tax laws or regulations. We regularly assess any significant exposure associated with increases in tax rates in international jurisdictions and adjustments are made as events occur that warrant adjustment to our tax provisions.

Our 2018 blended effective tax rate on foreign earnings is currently estimated to be approximately 15% for continuing operations. For the year, we expect to have positive income before taxes in our foreign jurisdictions but losses before taxes in U.S. jurisdictions due to our projected amounts of Interest Expense.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Liquidity and Capital Resources** |  |  |  |  |  |
|  |  | **September 28,** | |  | **December 29,** |
| (dollars in thousands) |  | **2018** |  |  | **2017** |
|  |  |  |  |  |  |
| Cash and cash equivalents | $ | 22,881 |  | $ | 37,341 |
| Working capital |  | 250,677 |  |  | 263,863 |
|  |  |  |  |  |  |
| Current ratio |  | 2.41 |  |  | 2.64 |
|  |  |  |  |  |  |

Cash and cash equivalents at September 28, 2018 decreased by $14.5 million from year-end as excess cash on hand was used to pay down our debt. Working capital from continuing operations decreased by $13.2 million from December 29, 2017, primarily due to the reduced cash balances.

At September 28, 2018, $10 million of our cash and cash equivalents were held by foreign subsidiaries. We intend to limit our distributions from foreign subsidiaries to previously taxed income. If distributions are made utilizing current period earnings, we will record foreign withholding taxes in the period of the distribution.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| ***Summary of Cash Flow*** |  |  |  |  |  |
|  |  | **Nine Months Ended** | | | |
|  |  |  | |  |  |
|  |  | **September 28,** | |  | **September 29,** |
| (in thousands) |  | **2018** |  |  | **2017** |
|  |  |  |  |  |  |
| **Cash provided by (used in):** |  |  |  |  |  |
| Operating activities | $ | 120,736 |  | $ | 115,570 |
|  |  |  |  |  |  |
| Investing activities |  | 549,155 |  |  | (34,702) |
| Financing activities |  | (692,896) |  |  | (91,317) |
|  |  |  |  |  |  |
| Effect of foreign currency exchange rates on cash and cash equivalents |  | 1,790 |  |  | 1,970 |
| Net change in cash and cash equivalents | $ | (21,215) |  | $ | (8,479) |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

The cash flow information presented includes cash flows related to the discontinued operations.

- 48 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**MANAGEMENT'S DISCUSSION AND ANALYSIS**

***Operating Activities*** *–*During the nine months ended September 28, 2018, we generated cash of $120.7 million from operations compared to $115.6 millionfor the nine months ended September 29, 2017. This increase was primarily due to a $26.4 million increase in cash income (i.e. income from continuing operations plus adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities) partially offset by a $21.2 million decrease in cash flow provided by working capital. The cash flow from working capital change during the period was primarily due to lower accrued interest as a result of our lower debt levels.

***Investing Activities*** *–*The $583.9 million increase in cash flows from investing activities was primarily attributable to net cash proceeds from the sale of theAS&O Product Line of approximately $582 million. Our current expectation is that capital spending for continuing operations for 2018 will be in the range of $37 million to $42 million, of which approximately half is discretionary in nature. We anticipate that cash on hand, cash flows from operations and available borrowing capacity under our Revolving Credit Facility will be sufficient to fund these capital expenditures. Property, plant, and equipment purchases related to our AS&O Product Line were approximately $15 million per year.

***Financing Activities –*** Net cash used in financing activities for the first nine months of 2018 was $692.9 million compared to $91.3 million in the comparable2017 period. Financing activities during the first nine months of 2018 included net payments of $670.1 million related to paying down our debt obligations compared to $106.5 million for the comparable 2017 period.

In connection with the completion of the sale of our AS&O Product Line, during the third quarter of 2018 we repaid $548 million of our debt, which included $360 million of our 9.125% Senior Notes, $114 million of our Term Loan B Facility and $74 million outstanding on our Revolving Credit Facility.

***Capital Structure –*** As of September 28, 2018, our capital structure consists of $954 million of debt outstanding under our Senior Secured Credit Facilitiesand 33 million shares of common stock outstanding. We have access to $191 million of borrowing capacity under our Revolving Credit Facility. We are also authorized to issue up to 100 million shares of common stock and 100 million shares of preferred stock. Our debt service obligations, comprised of principal and interest payments for the remainder of 2018, are estimated to be approximately $22 million.

Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents and potential borrowings under the Revolving Credit Facility should be sufficient to meet our working capital and fixed capital requirements for the next twelve months. If our future financing needs increase, we may need to arrange additional debt or equity financing. Accordingly, we evaluate and consider from time to time various financing alternatives to supplement our financial resources and optimize our capital structure. We cannot be assured that, if needed, we will be able to enter into any such arrangements on acceptable terms or at all.

***Credit Facilities*** - As of September 28, 2018, we had senior secured credit facilities (the “Senior Secured Credit Facilities”) that consist of (i) a $200 millionrevolving credit facility (the “Revolving Credit Facility”), which had letters of credit totaling $9 million drawn against it as of September 28, 2018, (ii) a $314 million term loan A facility (the “TLA Facility”), and (iii) an $658 million term loan B facility (the “TLB Facility”). The Revolving Credit Facility will mature on October 27, 2020, the TLA Facility will mature on October 27, 2021 and the TLB Facility will mature on October 27, 2022.

The Revolving Credit Facility and TLA Facility contain financial covenants requiring (A) a maximum total net leverage ratio (as defined in the agreement governing the Senior Secured Credit Facilities) of 5.75:1.0, subject to periodic step downs beginning in the fourth fiscal quarter of 2018 and (B) a minimum interest coverage ratio of adjusted EBITDA (as defined in the Senior Secured Credit Facilities) to interest expense of 2.75:1.0 subject to a step up beginning in the first quarter of 2019. As of September 28, 2018, our total net leverage ratio, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 3.4 to 1.00. For the twelve month period ended September 28, 2018, our ratio of adjusted EBITDA to interest expense, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 5.4 to 1.0.

Failure to comply with these financial covenants would result in an event of default as defined under the Revolving Credit Facility and TLA Facility unless waived by the lenders. An event of default may result in the acceleration of our indebtedness. As a result, management believes that compliance with these covenants is material to us. As of September 28, 2018, we were in full compliance with the financial covenants described above. However, a significant increase in the LIBOR interest rate or a decline in our operating performance, and in particular our sales or adjusted EBITDA, could result in our inability to meet these financial covenants and lead to an event of default if a waiver or amendment could not be obtained from our lenders. The Revolving Credit Facility is supported by a consortium of thirteen lenders with no lender controlling more than 27% of the facility.

Upon completion of the redemption in full of the Senior Notes in July 2018, the indenture governing the Senior Notes was satisfied and discharged. See Note 5 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for a further information on the Company’s outstanding debt.

- 49 -

[Table of Contents](#page2)

**INTEGER HOLDINGS CORPORATION**

**MANAGEMENT'S DISCUSSION AND ANALYSIS**

**Off-Balance Sheet Arrangements**

We have no off-balance sheet arrangements within the meaning of Item 303(a)(4) of Regulation S-K.

**Impact of Recently Issued Accounting Standards**

In the normal course of business, we evaluate all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission, or other authoritative accounting bodies to determine the potential impact they may have on our Condensed Consolidated Financial Statements. See Note 16 “Impact of Recently Issued Accounting Standards” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about these recently issued accounting standards and their potential impact on our financial condition or results of operations.

**Contractual Obligations**

Presented below is a summary of contractual obligations as of September 28, 2018, reflecting the redemption in full of the Senior Notes, repayment of our Term Loan B Facility and Revolving Credit Facility during the third quarter of 2018.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | **Payments due by period** | | | | | |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  | **More than 5** |
|  |  | **Total** | | **Less than 1 year** | | |  | **1-3 years** | |  | **3-5 years** | |  | **years** |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Total debt obligations | $ | 972,349 |  | $ | 37,500 |  | $ | 75,000 |  | $ | 859,849 |  | $ | — |
| Interest on debt(a) |  | 174,548 |  |  | 47,612 |  |  | 89,891 |  |  | 37,045 |  |  | — |

1. Interest payments in the table above reflect the contractual interest payments on our outstanding debt based upon the balance outstanding and applicable interest rates at September 28, 2018, and exclude the impact of the debt discount amortization and impact of interest rate swap agreements.

Refer to Note 5 “Debt” and Note 10 “Commitments and Contingencies” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for further discussion on our contractual obligations.

**Critical Accounting Policies and Estimates**

The preparation of our Condensed Consolidated Financial Statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Our estimates, assumptions and judgments are based on historical experience and various other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amount of assets and liabilities that are not readily apparent from other sources. Making estimates, assumptions and judgments about future events is inherently unpredictable and is subject to significant uncertainties, some of which are beyond our control. Management believes the estimates, assumptions and judgments employed and resulting balances reported in the Condensed Consolidated Financial Statements are reasonable; however, actual results could differ materially.

There have been no significant changes to the critical accounting policies and estimates as compared to those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 29, 2017.

- 50 -

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Refer to information appearing under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Form 10-Q. Furthermore, a discussion of market risk exposures is included in Part II, Item 7A, Quantitative and Qualitative Disclosure about Market Risk, of the Company’s Annual Report on Form 10-K for the year ended December 29, 2017. There have been no material changes in reported market risk since the inclusion of this discussion in the Company’s Annual Report on Form 10-K referenced above.

**ITEM 4. CONTROLS AND PROCEDURES**

1. Evaluation of Disclosure Controls and Procedures

Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the Securities and Exchange Commission as of September 28, 2018. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Based on their evaluation, as of September 28, 2018, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.

1. Changes in Internal Control Over Financial Reporting

During the Company’s most recent fiscal quarter, there have been no changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

- 51 -

**PART II—OTHER INFORMATION**

**ITEM 1.** **LEGAL PROCEEDINGS**

There were no new material legal proceedings that are required to be reported in the quarter ended September 28, 2018, and no material developments during the quarter in the Company’s legal proceedings as previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 29, 2017.

**ITEM 1A.** **RISK FACTORS**

There have been no material changes to the Company’s risk factors as previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 29, 2017.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **ITEM 6.** | |  | **EXHIBITS** | | | | | |
| **Exhibit** | |  |  |  |  |  |  |  |
| **Number** | |  |  | **Description** | | | | |
|  |  |  |  |  |  |  |  |  |
| 10.1#\* |  |  | [Employment Offer Letter, dated September 14, 2018, between Integer Holdings Corporation and Jason Garland.](#page54) | | | |  | |
| 31.1\* |  |  | [Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act.](#page60) | | | | | |
| 31.2\* |  |  | [Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act.](#page61) | |  |  | | |
| 32.1\*\* |  |  | [Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906](#page62) | | | | | |
|  |  |  | [of the Sarbanes-Oxley Act of 2002.](#page62) |  | | | |  |
| 101.INS\* | |  | XBRL Instance Document | | | | | |
| 101.SCH\* | |  | XBRL Extension Schema Document | | | | | |
| 101.CAL\* | |  | XBRL Extension Calculation Linkbase Document | | | | | |
| 101.LAB\* | |  | XBRL Extension Label Linkbase Document | | | | | |
| 101.PRE\* | |  | XBRL Extension Presentation Linkbase Document | | | | | |
| 101.DEF\* | |  | XBRL Extension Definition Linkbase Document | | | | | |

\* Filed herewith.

\*\* Furnished herewith.

* Indicates exhibits that are management contracts or compensation plans or arrangements.
  + 52 -

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 2, 2018 INTEGER HOLDINGS CORPORATION

By: /s/ Joseph W. Dziedzic



Joseph W. Dziedzic

President and Chief Executive Officer

(Principal Executive Officer)

By: /s/ Jason K. Garland



Jason K. Garland

Executive Vice President and

Chief Financial Officer

(Principal Financial Officer)

By: /s/ Tom P. Thomas



Tom P. Thomas

Vice President, Corporate Controller

(Principal Accounting Officer)

- 53 -

Kirk Thor

Executive Vice President & Chief Human Resources Officer

214.618.4984

kirk.thor@integer.net

September 14, 2018

Jason Garland

Dear Jason:

On behalf of Integer Holdings Corporation (“Integer” or the “Company”), I am pleased to present you with this offer for the position of Executive Vice President & Chief Financial Officer, reporting directly to the Company’s President & Chief Executive Officer. In that role, you will be a member of the Company’s Executive Leadership Team. Your position will be based at the Company’s offices in Plano, Texas. “Effective Date‟ as used in this letter will be the agreed upon employment start date.

You agree to the best of your ability and experience that you will, at all times, loyally and conscientiously perform all of the duties and obligations required of the position, and abide fully with the Company’s Code of Ethics.

During the term of your employment, you further agree that you will devote all of your business time and attention to the business of the Company and that you will not, directly or indirectly, engage or participate in any personal, business, charitable or other enterprise that is competitive in any manner with the business of the Company, whether or not such activity is for compensation.

**Compensation**

Through compensation, benefits and annual and long term incentive programs, Integer provides its Executives with significant opportunities on a reward for performance basis. The objective of these programs is to recognize and reward individual and Company performance.

Base Salary: As of the Effective Date, your base salary will be $430,000 per annum, earned and payable bi-weekly at a rate of $16,538.46. The Company will, in good faith, review your performance and salary on an annual basis beginning in 2020, and will consider appropriate increases in your salary based on your performance and the successful achievement of agreed upon objectives. The Company’s performance year is consistent with its fiscal year.

Incentive Awards: As a member of the Executive Leadership Team, you are directly awarded for your individual performance and impact on the Company’s short and long term success.

Beginning on the Effective Date, you will be eligible to participate in the Company’s Short Term Incentive (STI) plan. The STI plan provides an award reflecting your grade level and your contributions. Your 2018 STI incentive will be 65% of your base salary at target, pro rated based on



Jason Garland

September 14, 2018

the Effective Date. Depending on the performance results achieved, you can earn up to 150% of the total target bonus.

Beginning in 2019, you will be eligible to participate in the Company’s Long Term Incentive (LTI) Plan. Under the LTI plan you have the opportunity for equity awards at significant levels. It is intended to reward performance that drives Integer in the achievement of its strategic and operating goals. Your 2019 LTI incentive will be $690,000 at target. Based on the performance results achieved, you can earn up to 150% of the performance based target amounts.

Special Equity Grant: We also are pleased to provide you with an equity grant having an aggregate value of $600,000 consisting of Restricted Stock Units that will vest in three equal annual installments beginning on the first anniversary of the Effective Date. The number of Restricted Stock Units you will receive will be determined by dividing the award value by the closing price per share of the Company’s common stock on the New York Stock Exchange on the close of business on the Effective Date. Such award will be documented through a separate award agreement, which will be subject to approval by the Compensation & Organization Committee of the Board of Directors as soon as practicable.

Sign-On Cash Bonus: Upon the Effective Date, you will be eligible for a $50,000 cash award that will be paid to you along with your base salary in the first payroll after the Effective Date.

Your annual merit increase, STI, and LTI awards will be granted in conjunction with the Company’s annual performance review process, which generally concludes within 3 months of the end of the Company’s fiscal year. The STI and LTI awards are determined each year by the Board of Directors based on an individual’s role and performance. Your participation in both the STI and LTI plan is subject to the terms of the plans which the Company modifies from time to time in its discretion.

**Other Benefits**

You will be entitled to participate in the programs from time to time generally offered to Associates of the Company, which currently include medical, dental and vision coverage, a 401(k) plan, and other programs described in the attached benefit summary. You also will be entitled to participate in the additional programs offered to other Executive Officers of the Company. Those current benefits currently include the following:

Life Insurance: At the Company’s expense and subject to you meeting the underwriters’ insurability standards, term life insurance with a total face value of $1,000,000, with the death beneficiary designated by you.

**Integer.net**



**2**

Jason Garland

September 14, 2018

Disability: Participation in the Executive long term disability program currently providing a benefit equal to 60% of base salary and short-term incentive (short-term incentive is calculated using the average of payments from the last two years), subject to a monthly maximum payment of $18,000.

Executive Physical Examination: Consistent with our interest in you maintaining your personal health, eligibility for the key management Physical Examination Program.

Financial Planning Assistance: This benefit provides reimbursement of certain expenses incurred in connection with your personal financial and estate planning.

Director and Officer Liability and Fiduciary Insurance: You will be covered by the Company’s Director and Officer Liability Insurance policies. In addition, you will be covered by the Company’s fiduciary liability insurance for any service related to employee benefit plans.

Homeowner Relocation: You will be eligible to participate in the Company’s homeowner’s relocation program, as described in the enclosed policy and summary.

All plans, policies and programs are subject to change at any time at the sole discretion of the Company.

**Reimbursement of Expenses**

You will be reimbursed for reasonable expenses that you may incur on behalf of and at the request of the Company in the performance of your responsibilities and duties, with the expectation that you will exercise reasonable and prudent expense control practices that are subject to audit by a designated representative of the Compensation and Organization Committee. Given that you may be required to attend evening events and/or dinners, the Company will reimburse you for related business travel, hotel and meal expenses.

**Change of Control**

If your employment is terminated following a Change of Control, as defined under the Change of Control Agreement to be entered into between you and the Company, the form of which is enclosed, the Company will provide you with the payments and benefits to which you are entitled under the terms of the Change of Control Agreement.

**At-Will Employment**

In accepting this new position with the Company, you certify that you understand and accept that your employment will be on an at-will basis, and that except as expressly set forth herein neither you nor

**Integer.net**



**3**

Jason Garland

September 14, 2018

any Company representative has entered into a contract regarding the terms or the duration of your employment. As an at-will employee, you will be free to terminate your employment with the Company at any time, with or without cause or advance notice. Likewise, the Company will have the right to terminate your employment at any time, with or without cause or advance notice.

**Termination of Employment**

If at any time during your employment the Company terminates your employment for reason other than Cause, you will be entitled to receive a severance benefit, payable in a single lump sum cash payment, that is equal to the sum of one year of your current base salary at the time of your termination of employment and the amount the Company reasonably anticipates it would otherwise have contributed to the Company’s medical plan on your behalf for the 12 months following the date of termination, less applicable tax withholdings. As a condition of receipt of the severance benefit, you will be required to execute a Separation Agreement and Release satisfactory to the Company in its reasonable discretion within 45 days after the date of termination of your employment and not thereafter revoke the Separation Agreement and Release as permitted therein. If you timely provide an effective Separation Agreement and Release to the Company, the severance benefit will be paid on the 60th day following your termination of employment. Notwithstanding the foregoing, no severance benefit will be paid under this paragraph if a severance benefit is payable under the Change of Control Agreement.

If your employment is terminated for cause, you will not be eligible for the continuation of pay or benefits with the exception of accrued benefits. “Cause” means a material breach of this agreement, gross negligence or willful misconduct in the performance of your duties, dishonesty to the Company, or the commission of a felony that results in a conviction of law.

**Code Section 409A Compliance**

It is intended that all terms and payments under this letter comply with and be administered in accordance with Section 409A of the Internal Revenue Code (the “Code”) so as not to subject you to payment of interest or any additional tax under Code Section 409A. All terms of this letter that are undefined or ambiguous will be interpreted in a manner that is consistent with Code Section 409A if necessary to comply with Code Section 409A. If payment or provision of any amount or benefit under this letter at the time specified would subject such amount or benefit to any additional tax under Code Section 409A, the payment or provision of such amount or benefit will be postponed, if possible, to the earliest commencement date on which the payment or provision of such amount or benefit could be made without incurring such additional tax. The Company will, to the extent reasonably possible, amend this letter in order to comply with Code Section 409A and avoid the imposition of any interest or additional tax under Code Section 409A; provided, however, that no amendment is required if such amendment would change the amount payable by the Company under this letter.

**Integer.net**



**4**

Jason Garland

September 14, 2018

Notwithstanding any other provision of the letter, if it is determined that you are a Specified Employee and that any amount or benefit payable under this letter (a) is subject to Code Section 409A and (b) is payable solely because you have incurred a separation from service, then the amount or benefit will not be paid (or begin to be paid) prior to the date that is six months after the date of your separation from service (or, if earlier, your date of death). Payment of any amount or benefit to which you would otherwise be entitled during the first six months following the date of your separation from service will be accumulated and paid on the day that is six months after the date of your separation from service. For purposes of this letter, a “Specified Employee” is an individual who is determined to be a “specified employee” within the meaning of Code Section 409A.

Any reimbursement of expenses or in-kind benefits provided under this letter subject to, and not exempt from, Code Section 409A will be subject to the following additional rules: (i) any reimbursement of eligible expenses will be paid on or before the last day of the calendar year following the calendar year in which the expenses were incurred; (ii) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during any calendar year will not affect the amount of expenses eligible for reimbursement, or in-kind benefits to be provided, during any other calendar year; and (iii) the right to reimbursement or in-kind benefits will not be subject to liquidation or exchange for another benefit.

**Status of Offer**

This offer is contingent upon (1) the receipt of a negative result on your drug test, (2) the receipt of satisfactory results of a pre-employment background verification check, and (3) the acceptance of the Company’s Inventions, Non-Disclosure and Non-Solicitation Agreement. The federal government requires all employers to verify an employee’s eligibility to work in the United States. Please bring documentation with you on your first day of employment to prove your work eligibility status.

**Acceptance**

By accepting the offer presented in this letter, you represent that you are not currently bound by any contractual provisions (including a non-compete clause or other similar restriction, signed or agreed to with respect to your employment by any present or former employer) that prevents, hinders or limits your ability to work for the Company or any of its subsidiaries in the manner set forth in this letter.

To the extent that you have any confidential or proprietary information of any former employer, you acknowledge that you will keep all such information confidential and will not disclose or make available, directly or indirectly, at any time, any such information to the Company or any of its subsidiaries, managers or employees.

**Integer.net**



**5**

Jason Garland

September 14, 2018

To confirm your acceptance of this position, please sign this letter on the line below and return to my attention via email at

kirk.thor@integer.net.

Jason, we are looking forward to having you join Integer as a member of the Executive Leadership Team.

Sincerely,

/s/ Kirk Thor

Kirk Thor

Executive Vice President & Chief Human Resources Officer

Understood, agreed and accepted:

|  |  |  |  |
| --- | --- | --- | --- |
| /s/ Jason Garland\_\_\_\_\_\_\_\_\_\_ | | September 16, 2018 | |
| Jason Garland |  | Date |  |

Enclosures:

* Change of Control Agreement
* Officer Indemnification Agreement
* Inventions, Non-Disclosure and Non-Solicitation Agreement
* Integer Relocation Policy - Homeowner

**Integer.net**



**6**

**Exhibit 31.1**

**CERTIFICATION**

I, Joseph W. Dziedzic, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the fiscal quarter ended September 28, 2018 of Integer Holdings Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   1. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   2. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   3. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
   4. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditor and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
   1. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   2. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 2, 2018 /s/ Joseph W. Dziedzic



Joseph W. Dziedzic

President and

Chief Executive Officer

(Principal Executive Officer)

**Exhibit 31.2**

**CERTIFICATION**

I, Jason K. Garland, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the fiscal quarter ended September 28, 2018 of Integer Holdings Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   1. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   2. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   3. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
   4. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditor and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
   1. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   2. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 2, 2018 /s/ Jason K. Garland



Jason K. Garland

Executive Vice President and

Chief Financial Officer

(Principal Financial Officer)

**Exhibit 32.1**

**CERTIFICATION**

Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906

of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of Integer Holdings Corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report on Form 10-Q for the quarter ended September 28, 2018 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 2, 2018 /s/ Joseph W. Dziedzic



Joseph W. Dziedzic

President and

Chief Executive Officer

(Principal Executive Officer)

Dated: November 2, 2018 /s/ Jason K. Garland



Jason K. Garland

Executive Vice President and

Chief Financial Officer

(Principal Financial Officer)

This certification is being furnished solely to accompany this Form 10-Q pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and is not to be deemed incorporated by reference into any filing of the Company except to the extent the Company specifically incorporates it by reference therein.